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Selective Elimination of Malignant Melanoma Using the Novel Anti-tumor Agents, 
OSW-1 and PEITC 
Kausar Begam Riaz Ahmed, B. Tech., M.S. 
(Advisory Professor: Peng Huang, M.D., Ph.D.) 
Metastatic melanoma is amongst the most refractory of cancers. Drug resistance and 
lack of therapeutic selectivity are two main challenges to successful melanoma therapy. 
Herein, we investigated the mechanims of anticancer activity and therapeutic selectivity of 
two novel agents,  3β, 16β, 17α-trihydroxycholest-5-en-22-one 16-O-[2-O-4-
methoxybenzoyl-β-D-xylopyranosyl]- [1→3]-2-O-acetyl-α-L-arabinopyranoside (OSW-1) 
and β-Phenylethyl Isothiocyanate (PEITC) in melanoma.  
 OSW-1 inhibited melanoma cell viability at nanomolar concentrations with minimal 
toxicity to normal melanocytes. Mechanistic studies revealed that OSW-1 suppressed 
Disialoganglioside 3 Synthase (GD3S) gene expression in melanoma cells, leading to 
inhibition of gangliosides GD3 and GD2. GD3 is an abundantly expressed melanoma cell 
surface antigen with pivotal roles in cancer progression and invasion. OSW-1 promoted 
interaction between GD3 and mitochondrial voltage-dependent gating protein 1 (VDAC1). 
Subsequent VDAC1 activation and autophagic cell death was observed. Downregulation of 
VDAC1 ameliorated the cytotoxic effect of OSW-1 in melanoma, indicating that VDAC1 
was critical to mediating OSW-1’s activity. Studies with OSW-1 resistant melanoma cells 
revealed that elevated ganglioside expression may form the mechanistic basis for the 
selectivity of OSW-1 towards melanoma.  
 Melanoma cells are characterized by mitochondrial dysfunction and intrinsic 
oxidative stress compared to normal melanocytes. Reactive oxygen species (ROS) activate 
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pro-oncogenic signaling pathways that promote cancer progression and metastasis. However, 
an excessive overload of ROS, beyond the cellular tolerance threshold may trigger oxidative 
damage and cell death. The natural product PEITC induced apoptosis in malignant 
melanoma. Biochemical studies revealed that PEITC depleted cellular glutathione leading to 
ROS accumulation, mitochondrial damage and cell death. Glutathione inhibition was crucial 
to mediating PEITC’s activity since the glutathione precursor, N-Acetyl Cysteine reversed 
ROS elevation and PEITC induced death. Normal melanocytes with a much lower basal ROS 
capacity were resistant to PEITC. Drug combination effect of PEITC with Carmustine and 
Temozolomide was synergistic, suggesting that redox modulating strategies may be effective 
in attenuating chemoresistance to these agents.  
 My study outlines novel therapeutic strategies to effectively eliminate malignant 
melanomas. The intrinsic differences in ganglioside expression and redox status between 
normal and cancer cells may be exploited to selectively kill melanoma cells using OSW-1 
and PEITC, thus making these compounds worthy of further pre-clinical and clinical 
investigation. 
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Chapter 1: Introduction 
 1.1 Metabolic and biochemical alterations in melanoma 
1.1.1 Dysregulated lipid metabolism: role of gangliosides. 
 Altered metabolism is a hallmark of cancer cells (1, 2). In addition to exhibiting the 
warburg effect phenotype, aggressive cancers are also characterized by increased de novo 
lipogenesis which provides membrane building blocks for rapid proliferation, post-
translational protein modifications and cell signaling (3).  The expression of critical lipogenic 
enzymes such as fatty acid synthase (FASN), HMG Co-A reductase (HMGCR), acetyl-coA 
carboxylase (ACC) is upregulated in human cancers, including malignant melanoma (4, 5).  
 Increased expression of the key fatty acid synthesis enzyme, FASN is correlated with 
poor prognosis in breast cancer and melanoma (6, 7). Elevated fatty acid synthesis has been 
associated with a high proliferative index in prostate cancers (8). Aberrant fatty acid 
biosynthesis induced by FASN overexpression has been known to induce a cancer-like 
phenotype in non-cancer epithelial cells (9). Further, oncogenic signaling pathways also 
activated FASN leading to increased fatty acid biosynthesis. Yamauchi et al. (2011) 
demonstrated that the PI3K-Akt-mTORC1 oncogenic signaling in melanoma cells activates 
the steroid regulatory element binding protein (SREBP), which is the master transcription 
factor for lipid metabolism (10). SREBP, in turn, activates the downstream HMGCR enzyme 
leading to increased cholesterol biosynthesis. Inhibition of the PI3K-Akt-mTORC1-SREBP 
signaling axis resulted in reduced cholesterol levels in the cell membrane lipid rafts. 
Importantly, inhibition of this SREBP mediated cholesterol biosynthesis using 
pharmacological inhibitors suppressed Akt activation in lipid rafts and attenuated tumor 
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growth (10). Ganglioside GD3 positively regulated the lipogenic phenotype in melanoma 
cells by mediating Akt activation and thus the downstream cholesterol biosynthesis.   
 Gangliosides are sialic acid containing glycosphingolipids that are ubiquitously 
expressed in human cancers and regulate signals transduced at the membrane microdomains 
(11). In general, while disialic acid containing gangliosides (GD3, GD2, GD1) promote 
tumor cell proliferation, invasion and motility and are considered to be pro-oncogenic (11, 
12), monosialic acid containing gangliosides (GM3, GM2, GM1) are tumor suppressive and 
inhibit cell growth and metastasis (11, 13, 14). In melanoma, elevated levels of gangliosides 
GD3, GD2, GM3 and GM2 were reported (15). Normal melanocytes exhibited high 
expression of ganglioside GM3 and minimal levels of GD3 (16). This differential ganglioside 
expression was due to a very low expression of the GD3 synthesis regulating enzyme GD3 
synthase in normal melanocytes (16). Using GD3-negative mutant of SK-MEL-28 cells, 
Furukawa et al. (2011), demonstrated that GD3 expression contributed to increased 
phosphorylation of adaptor molecules, p130Cas, paxillin, and focal adhesion kinase (FAK). 
Further, higher localization of the Src kinase, Yes, to the lipid rafts in the cell membrane of 
GD3-positive SK-MEL-28 cells was observed. Also, enhanced integrin function and a higher 
localization of integrin to the ganglioside enriched microdomains (GEM)/lipid rafts in the 
GD3-positive SK-MEL-28 cells, where it clusters with GD3 on the rafts, was observed.  (17-
19). Thus ganglioside GD3 acts as a point of convergence for growth factor receptor-
mediated signaling and integrin mediated adhesion signaling, leading to activation of 
enhanced malignant signals and cancer phenotypes (figure 1.1) (18, 20). More significantly, 
injection of anti-GD3 monoclonal antibody suppressed tumor progression in melanoma 
tissues and patients making it an important target for melanoma therapy (21, 22). 
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 The ganglioside GD2 is overexpressed in breast and lung cancers. Battula et al. 
reported that GD2 is a stem cell marker in human breast cancer and may contribute to c-Met 
activation and chemoresistance in these cells (23, 24).  Anti-GD2 antibody treatment of small 
cell lung cancer (SCLC) cells led to dephosphorylation of FAK, activation of p38 MAPK and 
finally cell death by anoikis (25).  
 Majority of gangliosides are constituted in the lipid rafts, where they interact with the 
receptors and other downstream proteins. It was observed that overexpression of the lipid 
raft-resident protein, caveolin-1, led to the dispersion of GD3 from the lipid raft domains 
(26). Further, the fine structure in the ceramide group of GD3 expressed in lipid raft was 
reported to be different from GD3 located in non-raft cell fractions (26). Further, a 
translocation of GD3 to the mitochondria during cell death signaling, where it regulates 
microtubule polymerization and apoptotic induction, has also been reported (27). Further 
studies need to be undertaken to shed light on the complex roles of GD3 in melanoma 
biology. 
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Figure 1.1: 
 
 
               
 
Figure 1.1: Convergence of growth factor receptor-mediated and integrin mediated 
adhesion signaling pathways under GD3 expression in melanoma. 
Reprinted by permission of Oxford University Press on behalf of the Japanese Biochemical 
Society. 
(11): Furukawa K, Hamamura K, Ohkawa Y, Ohmi Y. Disialyl gangliosides enhance tumor 
phenotypes with differential modalities. Glycoconjugate journal. 2012;29(8-9):579-84. 
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1.1.2 Mitochondrial dysfunction  
 Mitochondria are dynamic cellular organelles which act as functional sites for 
oxidative phosphorylation, fatty acid oxidation, tricarboxylic acid cycle and execution of 
apoptosis (28, 29).  Cancer cells are characterized by Warburg effect, wherein the tumor cells 
rely on glycolysis rather than oxidative phosphorylation for their energy and metabolic needs 
due to defects in their mitochondrial respiratory machinery, decreased oxidation of NADH-
linked substrates or mitochondrial mutations. Increase in reactive oxygen species (ROS), due 
to various causes such as defects in electron transport, reduced ROS scavenging, 
environmental or oncogene induced stress etc., is a characteristic feature of cancer cell 
mitochondria (28). Enhanced ROS contributes to stabilization of hypoxia inducible factor-α, 
loss of p16, further oxidative damage and metastasis of cancer cells. In addition, mutations in 
mitochondrial DNA have also been observed. For instance, Tan et al. (2002) identified 
somatic mutations in the D-loop region, 16sRNA, ND2 and ATPase 6 genes of mitochondrial 
DNA in breast cancer patients (29, 30). In melanoma, a comprehensive analysis by Poetsch 
et al. (2004) discovered mitochondrial instability in the D-loop region in 13% of nodular 
primary cancers and 20% metastatic melanomas (31). Interestingly, the pro-oncogenic 
mutant BRAF, BRAF V600E localized to mitochondria in thyroid cancer cells leading to 
inhibition of oxidative phosphorylation, increased glycolytic activity and a high glucose 
uptake (32).     
   Mitochondrial autophagy or mitophagy is also activated in cancer cells as a cellular 
response mechanism to nutrient depletion (28). Various studies indicate that mitophagy is 
preceded by mitochondrial fragmentation and membrane permeabilization. The 
mitochondrial transition pore protein, voltage dependent anion channel 1 (VDAC1) has been 
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reported to induce apoptotic and autophagic cell death in cells (33-35). Recent studies by De 
Pinto et al. (2007) and Tomasello et al (2009) demonstrated that overexpression of human 
(h)VDAC1 caused depolarization of the inner membrane and triggered mitochondrial 
permeability transition (MPT), which may be followed by autophagy (33, 36). In cancer 
cells, the hypoxia regulated BNIP3/NIX proteins have been recognized as key players in 
mediating mitochondrial autophagy (28, 37). 
1.1.3 Redox homeostasis and oxidative stress  
 A unique feature of melanoma biology is the free radical generation by aberrant 
melanosomes (38). Reactive oxygen species play important roles in melanoma development, 
immune response, metabolism, and metastasis (38). Loss of PTEN and decreased PTEN 
activity is observed in about 20% of melanomas (39).  Activation of Akt signaling can 
promote ROS generation by inducing the expression of the ROS generating enzyme NOX4 
in melanoma cells and mice (40). Also, Akt may inhibit the activity of various pro-apoptotic 
proteins such as BAD and forkhead transcription factor (FOXO) thus stabilizing the cells 
with mitochondrial damage and potentiating ROS production. Further, MAPK which are 
activated in melanoma due to BRAF V600E activating mutation also modulate ROS 
generation in cells (41, 42). Further loss of function of the tumor suppressors, p53 and p16 
may also contribute to ROS stress phenotype (43). Chronic oxidative stress in combination 
with ultraviolet (UV) exposure may lead to malignant transformation of cells (38, 44, 45). 
ROS can activate the transcription factors, NF-κB and AP-1 thus promoting melanoma 
progression (46, 47). ROS generated by hypoxic mitochondria and NADPH oxidases may 
stabilize hypoxia inducible factor 1-α (HIF1-α) and potentially block PTEN mediated 
inhibition of Akt signaling leading to activation of downstream anti-apoptotic proteins 
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including Bcl-1 and Bcl-xL (48). Thus ROS plays pivotal roles in melanoma transformation 
and metastasis.  
 Reactive oxygen species function as a doubled-edged sword. Intrinsically high ROS 
levels in melanoma cells promote tumor development. However, if the ROS stress in 
melanoma is at a level that is beyond the cell’s toxicity tolerance threshold, then it may 
trigger cell death. Normal cells which have lower basal ROS stress levels and a reserve 
antioxidant capacity will be resistant to this ROS accretion since their antioxidants will be 
mobilized to neutralize the ROS increase and prevent it from reaching the cell-death 
threshold. The pro-oncogenic signaling in melanoma cells triggers increased ROS production 
and elevates the antioxidant capacity of the cells so as to neutralize the high level of free 
radicals being generated. Eventually, this results in a shift of redox dynamics and a high 
dependence of cancer on antioxidants to sustain the ROS levels within the cell’s toxicity 
threshold (49). Hence cancer cells are more vulnerable to redox modulatory or pro-oxidant 
based therapeutic strategies that by either scavenging the antioxidants or instigating 
excessive ROS production (for instance through inhibition of oxidative phosphorylation) may 
drive the ROS levels above the toxicity tolerance threshold of the cell leading to massive cell 
death (49). This therapeutic strategy is illustrated in figure 2. 
This therapeutic strategy is relatively novel and may find great utility in inducing cell 
death as well as combating drug resistance to other conventional melanoma 
chemotherapeutic agents. Currently, Elesclomal, a pro-oxidant compound that utilizes a 
similar mechanism of action is in clinical trials for melanoma (50-52). 
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Figure 1.2: 
 
 
 
 
                              
 
                          
                           
 
Figure 1.2: Altered redox dynamics between normal and cancer cells. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery, 
copyright 2009.  
(49): Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated 
mechanisms: a radical therapeutic approach? Nature reviews Drug discovery. 2009;8(7):579-
91. 
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1.2 Purpose and significance of this study 
 The purpose of this PhD dissertation was to characterize novel therapeutic strategies 
based on altered lipid metabolism and reactive oxygen species mediated stress in melanoma 
cells to selectively eliminate malignant melanomas using the novel anticancer agents, OSW-1 
and PEITC. 
 The rationale for this research design, study hypothesis and specific aims have been 
described in the sections below. 
1.2.1 Rationale for this study 
Selective elimination of malignant melanomas by OSW-1: 
 The ganglioside GD3 is highly expressed in a majority of melanoma cell lines and 
tissues (53, 54) and mediates cell proliferation and metastasis (17, 19). Hamamura et al. 
(2005) demonstrated that GD3 enhanced cell growth and invasion through FAK, p130cas and 
paxicillin signaling in melanoma cells (17). Enhanced integrin cluster formation in lipid rafts 
on the melanoma cell membrane was observed under GD3 expression suggesting that it 
contributed to adhesion signaling in malignant melanoma (19). Thus GD3 acts as a 
convergence point for growth factor and integrin-mediated adhesion signaling in melanoma 
cells (18, 20). Further, GD3 expression induced cholesterol biosynthesis, lipogenic 
phenotype and activation of Akt signaling in melanoma (10). Significantly, only trace 
amounts of GD3 were detected in normal melanocytes as compared to melanoma cells (16), 
thus highlighting its potential as a surface antigen that can be targeted to selectively eliminate 
melanoma cells with limited toxicity to the surrounding normal melanocytes. Currently, GD3 
is being investigated in melanoma immunotherapy (21, 22, 55). 
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 Recent studies identified that Triptolide, which bears structural similarities with 
OSW-1, inhibited ganglioside GD3 and GD2 expression in melanoma cells (56). Yokoyama 
et al. (2005), discovered that OSW-1 encapsulation in GM3 liposomes led to melanoma cell 
killing (57). These results suggested that OSW-1 might potentially inhibit ganglioside 
expression in melanoma cells. Previous studies from our lab have demonstrated that OSW-1 
induces cytotoxicity through mitochondrial dependent mechanisms in leukemia cells (58, 
59). Ganglioside GD3 translocates to mitochondria during cell death and through its 
interactions with the raft-like mitochondrial microdomains may have a regulatory function in 
inducing mitochondrial membrane permeabilization and apoptosis (27, 60).  
 The rationale for my research study was that OSW-1, because of its similarity to 
Triptolide and higher affinity towards GM3 may have an inhibitory effect on ganglioside 
(GM3, GD3, GD2) expression. Inhibition of ganglioside GD3, which plays important roles in 
melanoma proliferation and invasion, would promote melanoma cell death. Further, because 
of the melanoma cell specific expression of GD3, cell death due to GD3 inhibition by OSW-
1 may be selective towards cancer cells. It was essential to investigate the effect of GD3 in 
mitochondrial signaling since OSW-1 was previously to act through mitochondria dependent 
mechanisms.         
Effective elimination of melanoma by PEITC: 
 Increased ROS generation and altered redox status is observed in cancer cells 
compared to normal cells. Recent studies have suggested that this differential redox biology 
may be exploited to selectively target malignant cells, overcome drug resistance and improve 
the therapeutic activity of current clinically available anticancer agents (61).  
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 Melanoma cells are under a higher intrinsic oxidative stress compared to normal 
melanocytes due to oncogene activation and aberrant melanosome function (62). This 
elevated ROS promotes melanoma oncogenic transformation, invasion, metastasis and 
metabolism. However, if the ROS stress in cells is pushed beyond the cells’ tolerance limit 
either by using pro-oxidant compounds or by abrogating the cellular antioxidant capacity, it 
would lead to massive toxicity and cell death.  
 The anticancer agent PEITC causes ROS accumulation in cancer cells either through 
depletion of the antioxidant glutathione or by inhibiting oxidative phosphorylation (63, 64). 
In my research, I postulated that melanoma cells would be at a higher intrinsic oxidative 
stress than normal melanocytes, making them vulnerable to ROS stress based therapeutic 
strategies. PEITC, because of its ability to potentiate further ROS increase, will effectively 
eliminate melanoma cells. Normal melanocytes, which maintain basal redox homeostasis, 
will be able to withstand the exogenous ROS stress induced by PEITC to a certain extent, 
and thus would be less sensitive to PEITC or other redox modulating agents. Further, these 
principles of redox modulation by PEITC may be utilized in attenuating drug resistance to 
currently used anticancer agents such as Temozolomide and Carmustine.  
1.2.2 Background information on OSW-1 
The natural product, 3β, 16β, 17α-trihydroxycholest-5-en-22-one 16-O-[2-O-4-
methoxybenzoyl-β-D-xylopyranosyl]- [1→3]-2-O-acetyl-α-L-arabinopyranoside (OSW-1), 
an acylated disaccharide cholestane saponin molecule was originally isolated as a main 
constituent of the bulbs of Ornithogalum saundersiae (Liliaceae) (65-67). It is highly 
cytotoxic against several human cancer cell lines with half maximal inhibitory concentrations 
in the nanomolar range (58, 59, 68). It exhibited significantly higher inhibitory effect than 
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many clinically used anticancer agents including etoposide, adriamycin (ADM), taxol 
(TAX), cisplatin (CDDP), mitomycin c and methotrexate (MTX) in leukemia, pulmonary 
adenocarcinoma, mouse mastrocarcinoma, pancreatic and brain cancers (59, 67). 
Importantly,  adriamycin-resistant and camptothecin-resistant p388 leukemia as well as 
fludarabine refractory primary leukemia cells from chronic lymphocytic leukemia (CLL) 
patients were sensitive to OSW-1 suggesting that it had a unique mechanism of action that 
was different from these clinically used agents (59, 67).  In vivo evaluation showed that it 
was extremely potent against mouse p388 tumors with a single 0.01 mg/kg dose increasing 
life span by 59% (67). Importantly, OSW-1 was therapeutically selective towards malignant 
cells with half-maximal inhibitory concentrations (IC50) 40- to 150-fold higher in normal 
cells than cancer cells (59). 
An in vitro screen against the National Cancer Institute (NCI)-60 cell line panel 
indicated that OSW-1 exhibited significant toxicity with an IC50 of 0.78 nM (67). Melanoma 
cells were specifically sensitive to OSW-1. Further Pearson’s correlation analysis using 
NCI’s COMPARE algorithm generated a Pearson’s correlation co-efficient between 0.6 and 
0.83 for OSW-1 vs. cephalostatin 1 suggesting that they had related mechanisms of action 
and shared cellular targets (67, 69). Structure activity relationship (SAR) analysis by Guo et 
al., identified that OSW-1 was analogous to one-half of the cephalostatin molecule with C22-
oxocarbenium ions playing a common role in the bioactivity of both OSW-1 and 
cephalostatin (68). Structural studies also revealed that the acetyl (Ac) and the 4-
methoxybenzoyl (MBz) groups on the disaccharide moiety of OSW-1 were essential as their 
removal diminished its cytotoxicity by 1000 fold (67, 70). In addition, the steroidal aglycone 
was critical to OSW-1’s potent cytotoxicity since SAR analysis indicated that substituting the 
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aglycone group on the steroidal backbone of OSW-1 with a totally disparate synthetic 
aglycone, while still retaining the disaccharide moiety, resulted in the compound not 
exhibiting any cytotoxic effects even at a concentration of 10 µM (66, 68, 71, 72). Thus both 
the disaccharide and aglycone groups are important to the antineoplastic activity of OSW-1. 
The first chemical synthesis of OSW-1 was reported by Deng et al. (1999), with an overall 
yield of 6% and 14 steps (73). Later, Yu et al. (2002), published an improvised synthesis 
procedure which reduced the total chemical synthesis steps to 10 and improved the overall 
yield to 28% (74). These findings inspired several studies on the synthesis and in vitro 
cytotoxic activity of OSW-1 analogues. Of specific interest to this dissertation, is the 
synthesis of biotinylated OSW-1 which is 10-times less toxic to cells than OSW-1 and may 
be used as a tool to identify the cellular interacting partners of OSW-1 (75).  
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      Figure1.3: Structure of OSW-1.  
      Chemical formula: C47H68O15  
                                          Molecular weight: 873.03 
Reprinted by permission from Macmillan Publishers Ltd: Nature Chemical Biology 
copyright 2011. 
 (69): Burgett AW, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K, 
Okubo S, Fortner KC, Mimaki Y, Kuroda M, Murphy JP, Schwalb DJ, Petrella EC, Cornella-
Taracido I, Schirle M, Tallarico JA, Shair MD. Natural products reveal cancer cell 
dependence on oxysterol-binding proteins. Nature chemical biology. 2011;7(9):639-47. 
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Despite  numerous studies on the chemical synthesis, bioactivity and structure activity 
relationship (SAR) of OSW-1 and its analogues, the mechanisms underlying the antitumor 
effect of this inhibitor are still not completely understood (67, 73-79). Tamura et al., 
demonstrated that OSW-1 directly inhibited gene expression of the ovarian steroidal limiting 
enzyme, cholesterol side chain cleavage cytochrome P-450 (p450scc), leading to suppression 
of ovarian estradiol secretion and granulosa cells proliferation in the ovary (80). Mechanistic 
studies from our lab revealed that OSW-1 inhibited the sodium-calcium exchanger 1 (NCX1) 
on the plasma membrane of leukemia cells, leading to cellular calcium overload, cytochrome 
c release and mitochondria dependent apoptosis (58). The mitochondrial respiration deficient 
human leukemia cells (HL60 C6F) were less sensitive to OSW-1 than the parental HL60 
cells, suggesting that OSW-1 mediated cell death was through mitochondria dependent 
mechanisms. Burgett et al. (2011),  identified the oxysterol binding protein (OSBP) and its 
closest paralog, OSBP-related protein 4L (ORP4L) as cellular binding targets of OSW-1 and 
cephalostatin, thus implying a role for these compounds in signal transduction, lipid transport 
and lipid metabolism (69). OSW-1 also induced necroptotic death in hepatocellular 
carcinoma through inhibition of cell invasiveness, angiogenesis, cell polarity and adhesion 
signaling, in addition to promoting mitochondria dependent apoptosis (81). Recently Yamada 
et al., identified endoplasmic reticulum (ER), golgi apparatus and to a lesser extent 
mitochondria as putative subcellular sites of OSW-1 localization (82).  
Atomic force microscopy studies by Yokoyama et al. (2005), identified that OSW-1 
distributed in the ganglioside GM3-phospholipid membrane monolayer in cells (83). Further, 
a strong attractive interaction between OSW-1 and GM3 was observed which seemed to be 
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related to the potent activity of OSW-1 against cancer cells. Specifically, treatment of B16-
F0 melanoma cells with OSW-1 encapsulated in ganglioside GM3 liposomes led to a 
complete inhibition of cell viability within 48 h (57). Interestingly, Triptolide, a structural 
analogue of OSW-1, suppressed the gene expression of GD3 synthase (GD3S), the rate 
limiting enzyme for GD3 biosynthesis, in melanoma and breast cancer cells (24, 56). 
Gangliosides are glycosphingolipids containing sialic acids which have been reported to be 
overexpressed in carcinomas of the lung, breast, neuroblastoma and melanoma (24, 53, 54, 
84-86). Ganglioside, GD3 is overexpressed in melanoma and is a well characterized 
therapeutic target (21).  
These research findings describe a role for OSW-1 in ganglioside biology and 
mitochondria dependent cell signaling. Through my PhD research, I sought to investigate the 
effect of OSW-1 on ganglioside GM3/GD3 expression and mechanisms of mitochondria 
dependent cell death in melanoma cells. Further, I conducted mechanistic studies to delineate 
the molecular mechanisms underlying the therapeutic selectivity of OSW-1 towards 
melanoma cells. The results and discussion in Chapter 3 focus on the important outcomes of 
my research with the antitumor agent OSW-1 in melanoma.  
1.2.3 Background information on PEITC 
The natural product β-Phenylethyl Isothiocyanate (PEITC) is an active metabolite of 
cruciferous vegetables such as broccoli, cauliflower and watercress (87). It exhibits 
chemopreventive properties by inhibiting the activity of the transcription factor, Nuclear 
Factor κB (NF-κB), which plays an important role in inflammation, cancer progression and 
survival. NF-κB is regulated by the protein IκBα, which sequesters NF-κB in the cytosol thus 
preventing its nuclear translocation and activation of downstream pro-inflammatory and 
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oncogenic genes (88). IκBα is a well characterized target of PEITC in prostate cancer (89). 
PEITC stabilizes IκBα expression thus inhibiting NF-κB activation, nuclear translocation of 
p65, and promotes suppression of NF-κB mediated VEGF, cyclin D1, Bcl-xL, iNOS and 
COX-2 protein expression (89-91).  
Numerous studies have reported that PEITC induces apoptosis in cancer cells, both in 
in vitro and in vivo settings (63, 87, 92-94) . This apoptosis induction by PEITC was 
characterized by G2-M cell cycle arrest, inhibition of the anti-apoptotic proteins, Bcl-xL, 
Bcl-2 and Mcl1 and caspases 8 and 9 cleavage in prostate cancer and leukemia cells (95). Mi 
et al., identified tubulin as an important binding target of PEITC in A549 lung cancer cells 
(96). This study demonstrated that the covalent binding of PEITC and other isothiocyanates 
to the tubulin proteins leads to disruption of microtubule polymerization, cell cycle arrest, 
down regulation of cyclins A, D and E and cell death (96, 97). Interestingly, apoptosis 
initiation in HT-29 colon cancer cells by PEITC was dependent upon activation of the MAP 
kinase, JNK. Consequently SP600125, an anthrapyrazolone inhibitor of JNK suppressed 
apoptosis by PEITC (98).  
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                                 Figure 1.4: Structure of PEITC 
       Chemical formula: C9H9NS  
                                                 Molecular weight: 163.24 
Reprinted with permission from (99): Moon YJ, Brazeau DA, Morris ME. Dietary phenethyl 
isothiocyanate alters gene expression in human breast cancer cells. Evidence-based 
complementary and alternative medicine : 2011. 
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PEITC mediated cytotoxicity in cancer cells was unique because of two observations: 
(a) PEITC treatment in cells led to excessive reactive oxygen species (ROS) generation (63, 
64, 94, 100-102). Recent studies have attributed this ROS production to two mechanisms – 
glutathione depletion and inhibition of oxidative phosphorylation by PEITC. This ROS stress 
was of functional significance and correlated with cell death in cancer cells. In addition, the 
ROS induction by PEITC was instrumental in ameliorating drug resistance to clinically used 
anticancer agents such as Gleevec, Vorinostat and Fludarabine in leukemia cells.  
(b) The cell death induced by PEITC was limited towards malignant cells with little 
cytotoxicity against normal cells (63, 64, 94, 103). Previous studies in our lab demonstrated 
that this preferential PEITC-cytotoxicity was due to altered redox biology between normal 
and cancer cells. Mitochondrial respiration deficient Rho-0 prostate cancer cells were also 
resistant to the antiproliferative activity of PEITC suggesting that the therapeutic selectivity 
of PEITC relies on mitochondria dependent mechanisms.   
 My PhD dissertation was focused on investigating the mechanisms of cytotoxicity 
and therapeutic selectivity of PEITC against melanoma cells. I had been particularly 
interested in examining if the redox differences between normal melanocytes and melanoma 
cells could be used as a therapeutic basis to preferentially eliminate melanoma cells. Further, 
mechanistic studies were undertaken to characterize the utility of PEITC to combat drug 
resistance to clinically used melanoma drugs such as Temozolomide and Carmustine. The 
results from my study on the anticancer activity of PEITC in melanoma have been discussed 
in chapter 4.     
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 1.3 Research hypothesis and specific aims 
 The central research hypothesis for my PhD dissertation was - alterations in reactive 
oxygen species (ROS) and lipid metabolism in melanoma cells, as compared to normal 
melanocytes, may serve as a biochemical basis to preferentially kill malignant melanoma 
cells using proper pharmacological agents such as OSW-1 and PEITC. 
 To address this hypothesis I identified the following two specific aims: 
1. To investigate altered lipid metabolism as the biological basis to preferentially 
eliminate melanoma cells using OSW-1. 
2. To investigate ROS stress as a biochemical basis to selectively kill melanoma cells 
using PEITC. 
 In order to effectively achieve both of these specific aims, each specific aim was 
further divided into three sub aims. Experiments were designed to investigate each of these 
sub aims. The specific aims and the corresponding sub aims have been listed below:  
Specific aim 1: To investigate altered lipid metabolism as the biological basis to 
preferentially eliminate melanoma cells using OSW-1. 
a) To determine the effect of OSW-1 on ganglioside expression in melanoma cells. 
b) To investigate the effect of OSW-1 on mitochondrial functionality in melanomas. 
c) To characterize the molecular mechanisms underlying the therapeutic selectivity of 
OSW-1 towards melanoma cells. 
Specific aim 2: To investigate ROS stress as a biochemical basis to selectively kill melanoma 
cells using PEITC. 
a) To determine the antiproliferative effect of PEITC in melanoma cells. 
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b) To characterize the underlying redox mechanisms that are pivotal to PEITC’s activity 
in melanoma cells.   
c) To elucidate therapeutic strategies to combat drug resistance in melanoma using 
PEITC. 
 The following chapters describe the project design, results obtained, key conclusions 
from my study and the future directions of my research.  
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Chapter 2: Materials and Methods 
2.1 Chemicals and reagents 
The compound OSW-1 was kindly provided by Dr. Zhendong Jin from the University of 
Iowa (Iowa City, Iowa). Β-Phenylethyl Isothiocyanate (PEITC) was purchased from Sigma-
Aldrich (St. Louis, MO). The original stock solutions of OSW-1 and PEITC were prepared in 
DMSO. For all experiments, OSW-1 and PEITC were diluted in the media at a concentration 
of 0.1% or less of the solvent DMSO. The fluorescent dyes Rhodamine 123, calcium green-1 
AM, mitotracker red CMXRos, Dihydroethidium and mitoSOX red mitochondrial 
superoxide indicator were purchased from Life Technologies (Grand Island, NY). Annexin 
V-FITC and the 10X binding buffer were purchased from BD Pharmingen (San Jose, CA). 3-
(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetra-zolium bromide (MTT), Giemsa stain, 4,4'-
diisothiocyano stilbene-2,2'-disulfonic acid (DIDS), Cyclosporin A (CsA), 3-Methyladenine 
(3-MA), Chloroquine (CQ),  Triptolide, and propidium iodide (PI) were purchased from 
Sigma-Aldrich (St. Louis, MO). 
2.2 Cell culture 
The melanoma cell lines A375P, A2058, WM115 were purchased from American Type 
Culture Collection (ATCC, Manassas, VA). A375SM, WM35, WM46, MEWO, MEL624, 
SK-MEL-2, UCSD-354L, and Hs294T cell lines were purchased from the characterized cell 
line core at University of Texas MD Anderson Cancer Center (Houston, TX); these cell lines 
were validated at the core facility by STR finger printing. The normal human epithelial 
melanocytes (NHEM) were purchased from Promocell (Heidelberg, Germany). NHEM cells 
were cultured in M254CF medium (Life Technologies, Long Island, NY) supplemented with 
PMA-free human melanocyte growth supplement-2 (Life Technologies, Long Island, NY) 
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and were grown at 37 ºC, 5% CO2 in a cell culture incubator. MEF VDAC1-/- cells were a 
generous gift of Dr. William Craigen (Baylor College of Medicine, Houston, TX) and were 
cultured in DMEM medium supplemented with 10% heat inactivated fetal bovine serum 
(FBS) and sodium pyruvate. A375P, A375SM, A2058 cells cultured in DMEM medium 
(Mediatech, Manassas, VA) supplemented with 10% heat inactivated FBS were grown in a 
cell culture incubator with 5% CO2 at 37 ºC in humidified air. WM35, WM46, WM115, 
MEWO, MEL624, SK-MEL-2, UCSD-354L, and Hs294T cells were grown in RPMI 1640 
medium (Mediatech, Manassas, VA) supplemented with 10% heat inactivated FBS in a cell 
culture incubator with 5% CO2 at 37 ºC in humidified air.  
2.3 MTT assay for cell viability 
Cell growth inhibition induced by OSW-1 and PEITC was assayed by performing the MTT 
assay as previously described (104). Briefly, melanoma cells, seeded in 96-well plates, were 
treated with log-scale serial diluted concentrations of OSW-1 and PEITC. After 72 h of 
incubation, 50 µl of MTT reagent per well was added for 4h. The cell media was then 
aspirated, formazan precipitates dissolved in DMSO and absorbance at 570 nm was 
measured in a Multiskan MK3 microplate-reader (Thermo Labsystem, Franklin, MA). The 
50% inhibitory concentration (IC50) values were then computed using GraphPad Prism 
(GraphPad Software, Inc. La Jolla, CA). 
2.4 Colony formation assay 
The colony formation assay was performed as described previously (105). Briefly,  
melanoma cells (5000 cells/well) were seeded in a 6-well plate and treated with varying 
concentrations of inhibitors for 2 weeks. The cells were then fixed with methanol/acetic acid 
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(10:1) solution, and stained with Giemsa (Sigma-Aldrich, St. Louis, MO). The cells were 
photographed and the colonies counted. 
2.5 Mitochondrial membrane potential measurement by Rhodamine 123 staining 
Rhodamine 123 assay was used to monitor the integrity of mitochondria following drug  
treatments as previously described (106, 107). Melanoma cells or normal melanocytes were 
treated with OSW-1, PEITC or other inhibitors for the indicated time points and then 
incubated in 0.5 µM rhodamine 123 dye during the last 1 h of drug treatment. The cells were 
then dissociated, washed twice with PBS and ∆Ψm measured using a BD Biosciences 
FACSCalibur flow cytometer (Mountain View, CA). Data analysis was performed using 
FlowJo (TreeStar Inc., Ashland, OR). 
2.6 Annexin-V/PI analysis for apoptosis 
Cell death by apoptosis/necrosis was measured by flow cytometric analysis of cells dual 
stained for annexin V-FITC and propidium iodide (108). Briefly, melanoma cells grown in 6-
well plates were treated with inhibitors for the indicated time points, harvested and stained 
with annexin V-FITC for 15 minutes, washed and then stained for propidium iodide. Cell 
death was measured using a BD Biosciences FACSCalibur flow cytometer (Mountain View, 
CA) and the results were analyzed using the FlowJo software (TreeStar Inc., Ashland, OR). 
2.7 Electron microscopy 
The electron microscopy experiment was performed at the high resolution electron 
microscopy facility (core grant CA16672) at the MD Anderson cancer center, as per the 
core’s prescribed protocol. Briefly, melanoma cell samples were fixed with a solution 
containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3, 
for 1 h. After fixation, the samples were washed and treated with 0.1% Millipore-filtered 
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cacodylate buffered tannic acid, post-fixed with 1% buffered osmium tetroxide for 30 min, 
and stained en bloc with 1% Millipore-filtered uranyl acetate. The samples were dehydrated 
in increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The 
samples were polymerized in a 70 ºC oven for 2 days. Ultrathin sections were cut in a Leica 
Ultracut microtome (Leica, Deerfield, IL), stained with uranyl acetate and lead citrate in a 
Leica EM Stainer, and examined in a JEM 1010 transmission electron microscope (JEOL, 
USA, Inc., Peabody, MA) at an accelerating voltage of 80 kV. Digital images were obtained 
using the AMT Imaging System (Advanced Microscopy Techniques Corp, Danvers, MA).  
2.8 Immunoblotting 
Immunoblotting was performed to assess protein expression in drug treated and control cell 
lysates (109). Proteins were separated on 10-15% SDS-PAGE gels, transferred onto 
nitrocellulose membranes and immunoblotted using the following commercially available 
antibodies: β-actin (Calbiochem, San Diego, CA), LC3B (Novus Biologicals, Littleton, CO), 
VDAC1 (Abcam, Cambridge, MA), phosphorylated and total ERK1/2, and Caveolin (Cell 
Signaling Technology, Inc., Danvers, MA). Membranes were then incubated with 
appropriate horseradish peroxidase conjugated secondary antibodies and the signal visualized 
using supersignal enhanced chemiluminescence kit (Thermo Scientific, Rockford, IL). 
2.9 Detection of ganglioside expression by flow cytometry 
Assessment of ganglioside expression changes following drug treatment was performed by 
flow cytometry as previously reported (24). Melanoma cells were treated with OSW-1 or 
other inhibitors for the indicated time durations, harvested, washed twice in PBS and stained 
for 30 min, 4 ºC, with the following commercially available antibodies: PE-anti human 
ganglioside GD2 (Biolegend, San Diego, CA), disialoganglioside GD3 (BD Biosciences, San 
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Jose, CA) and anti GM3 (NeuAc) antibody (Cosmo Bio USA, Inc., Carlsbad, CA). Samples 
stained with PE-conjugated GD2 antibody were washed and directly assayed using the BD 
Biosciences FACSCalibur flow cytometer (Mountain View, CA). Samples probed with GM3 
and GD3 antibodies were washed, stained with a FITC-conjugated secondary antibody for 
another 30 min, 4 ºC and the GM3/GD3 expression was measured by flow cytometry. All 
data analysis was performed using FlowJo (TreeStar Inc., Ashland, OR). 
2.10 Lipid raft / ganglioside enriched microdomain (GEM) isolation 
The lipid raft fractions were prepared using a detergent extraction protocol described by 
Mitsuda et al (110). Two T-175 flasks of 80-90% melanoma cells were used for each 
preparation. Briefly, cells were harvested, washed twice in ice-cold PBS and suspended in 1 
mL of TNE buffer (1% Triton X-100, 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
EGTA). The cells were then dounce homogenized 24 times, mixed with equal volume of 
80% sucrose and placed at the bottom of ultra-clear centrifuge tubes (Beckman Coulter, 
Brea, CA). 2 mL of 30% sucrose solution in TNE buffer without Triton X-100 and 1 mL of 
5% sucrose solution in TNE buffer without Triton X-100 were carefully laid on top of the 
preparation. The samples were then centrifuged at 105,000 × g in a Beckman Coulter Optima 
XPN-100 ultracentrifuge (Brea, CA) for 16 h at 4°C.  From the top of the gradient, 9 
fractions of 0.5 mL sample were collected and assayed by SDS-PAGE or dot blot. 
2.11 Real time RT-PCR 
To analyze mRNA expression of GD3S, GD2S, FASN and HMGCR, real time RT-PCR was 
performed as previously described (111).  Briefly, total RNA was extracted from melanoma 
cells using the RNeasy mini kit (Qiagen, Valencia, CA). 2 µg of RNA was subjected to 
reverse transcription with random hexamer primers utilizing the revertaid first strand cDNA 
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synthesis kit (Thermo Scientific, Pittsburg, PA). Real time PCR was performed on an 
Applied Biosystems Viia7 machine using SYBR green with the following cDNA primers:  
FASN forward: 5’ – CGCTCGGCATGGCTATCT-3’; FASN reverse: 5’-
CTCGTTGAAGAACGCATCCA-3’; HMGCR forward: 5’-GGCCCAGTTGTGCGTCTT-
3’; HMGCR reverse: 5’-CGAGCCAGGCTTTCACTTCT-3’; GD3S forward: 5’- 
TGTGGTCCAGAAAGACATTTGTGGACA-3’; GD3S reverse: 5’- 
TGGAGTGAGGTATCTTCACATGGGTCC-3’; GD2S forward: 5’- 
GACAAGCCAGAGCGCGTTA-3’ and GD2S reverse: 5’- 
TACTTGAGACACGGCCAGGTT-3’. All experiments were performed with three 
biological replicates and three technical replicates and the results have been reported as the 
mean of the biological replicates plus or minus standard error. 
2.12 Immunofluorescence staining and confocal microscopy 
Immunofluorescence staining and confocal microscopic analysis were performed based on 
previously reported protocols (10, 112). Melanoma cells were cultured on sterilized glass 
coverslips, treated with OSW-1 and incubated in 50 nM mitotracker red for 25 min. Cells 
were washed twice with PBS, fixed with 3.7% paraformaldehyde in medium at 37 °C for 
10 min, permeabilized using 0.3% Triton X-100 for 10 minutes, washed and then blocked 
with 4% FBS for 1 h. The samples were incubated overnight with the disialoganglioside GD3 
(BD Biosciences, San Jose, CA) and/ or VDAC1 (Proteintech, Chicago, IL) antibodies, 
washed and incubated in FITC- and rhodamine red X-conjugated secondary antibodies 
(Jackson Immunoresearch Laboratories, Inc., West grove, PA) for 1 h. The samples were 
then washed and mounted onto glass slides using the Ultracruz mounting medium (Santa 
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Cruz Biotechnology, Dallas, TX). Images were taken by NIKON Eclipse TE2000 confocal 
microscope and analyzed using the Nikon EZ-C1 software. 
2.13 Cytosolic calcium detection 
Cytosolic calcium levels were measured as previously described (109). Briefly, melanoma 
cells were treated with OSW-1 or other inhibitors for the indicated time durations, harvested, 
washed twice in PBS and stained with calcium green fluorescent dye for 30 min at 4 ºC. 
Cytosolic calcium levels were detected in the FL-1 channel of the BD Biosciences 
FACSCalibur flow cytometer (Mountain View, CA). 
2.14 Detection of cellular free radical expression by staining with the fluorescent dyes 
DCFDA, DAF-FM, Dihyroethidium and mitoSOX mitochondrial superoxide indicator 
Flow cytometric measurements using the CM-H2-DCFDA, DAF-FM or Dihydroethidium 
fluorescent probes was performed to detect free radical levels in cells (63, 113).  Briefly, 
melanoma cells were treated with OSW-1, PEITC or other inhibitors for the indicated time 
points and then incubated in 1 µM mitosox red or CM-H2-DCFDA or DAF-FM or 
Dihydroethidium during the last 1 h of drug treatment. The cells were then dissociated, 
washed twice with PBS and the free radical expression levels were measured using a BD 
Biosciences FACSCalibur flow cytometer (Mountain View, CA). Data analysis was 
performed using FlowJo (TreeStar Inc., Ashland, OR). 
2.15 siRNA transfection 
Tranfection of VDAC1 and control siRNAs was performed as previously reported (114). 
Briefly, A375SM melanoma cells were plated in a 6-well plate and cultured until 50% 
confluency, at which point, they were transfected with 50 nM silencer select siVDAC1 (ID: 
s14769) or the negative control siRNA (Life Technologies, Long Island, NY) by the 
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Lipofectamine RNAiMAX reagent (Life Technologies, Long Island, NY). Western blot was 
performed to determine VDAC1 expression 48 h post-transfection.   
2.16 Glutathione assay 
A glutathione assay kit (Cayman Chemicals, Ann Arbor, MI) was used to detect cellular 
glutathione levels (63, 94, 113). Cell extracts were obtained by sonication (power setting - 4, 
10 s 3X) and deproteination as per the manufacturer’s guidelines. The reaction product of 
glutathionylated 5, 5’-dithiobis-(2-nitrobenzoic acid) was detected spectrophotometrically 
using the Multiskan MK3 microplate-reader (Thermo Labsystem, Franklin, MA) at 450 nm. 
A standard curve for glutathione was generated and the glutathione concentration in each 
sample was calculated. The Bicinchoninic Acid (BCA) assay was performed to determine 
sample protein concentration and to normalize the glutathione concentration across samples. 
GraphPad Prism (GraphPad Software, Inc. La Jolla, CA) was used to perform all statistical 
analysis. 
2.17 Reverse phase protein array (RPPA) analysis 
The RPPA experiments were performed at the functional proteomics reverse phase protein 
array core (NCI # CA16672) at the MD Anderson cancer center, following the core’s 
experimental protocols (115). Briefly, melanoma cells lysates were extracted in the following 
lysis buffer: 1% Triton X-100, 50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM 
EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, containing 
freshly added protease and phosphatase inhibitors. Cellular proteins were denatured by 1% 
SDS (with beta-mercaptoethanol) and diluted in five 2-fold serial dilutions in dilution buffer 
(lysis buffer containing 1% SDS). Serial diluted lysates were arrayed on nitrocellulose-coated 
slides (Grace Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Sample slides were 
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probed with 217 primary antibodies and the corresponding biotin-conjugated secondary 
antibody. The signal obtained was amplified using a Dako Cytomation–catalyzed system 
(Dako) and visualized by DAB colorimetric reaction. The slides were scanned, analyzed, and 
quantified using a customerized-software Microvigene (VigeneTech Inc.) to generate spot 
intensity. Each dilution curve was fitted with a logistic model (“Supercurve Fitting” 
developed by the Department of Bioinformatics and Computational Biology in MD 
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). The protein 
concentration of each set of slides was then normalized by median polish, which was 
corrected across samples by the linear expression values using the median expression levels 
of all antibody experiments to calculate a loading correction factor for each sample. Heat 
maps were generated in Cluster 3.0 (http://www.eisenlab.org/eisen/) as a hierarchical cluster 
using Pearson Correlation and a center metric. The resulting heatmap was visualized in 
Treeview (http://www.eisenlab.org/eisen/).  
2.18 Statistical analysis 
Statistical analysis was computed using GraphPad Prism version 6 (La Jolla, CA). Data were 
graphed as mean ± standard error (SEM) for experiments performed in triplicates unless 
noted differently. A standard student’s two tailed t-test was performed to determine 
statistically significant difference between samples at a 95% confidence interval.  In all 
cases, **** denotes p < 0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 
0.05.  
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Chapter 3: The anti-tumor agent, OSW-1, effectively eliminates melanoma cells 
through ganglioside GD3 and mitochondrial VDAC1 dependent mechanisms  
3.1 Introduction 
The natural product OSW-1 is a highly potent anticancer agent. Previous studies both 
from our lab and others demonstrated that OSW-1 inhibited cancer cell viability at sub-
nanomolar concentrations with minimal toxicity towards normal cells (67, 81). Further, it 
was effective in eliminating various cancer cells including leukemia, glioblastoma and 
pancreatic cancers that were resistant to other clinically used agents such as taxol, adriamycin 
and fludarabine (59, 67).  
Previous research efforts from our lab revealed that OSW-1 inhibited the sodium-
calcium exchanger 1 (NCX1) on the cell membrane of HL-60 leukemia cells, leading to 
cytosolic calcium elevations, caspase 3 activation and mitochondria dependent apoptosis 
(58). However, the mechanisms of OSW-1 induced cytotoxicity in solid tumors still remain 
to be elucidated. Recent studies demonstrated that steroidal compounds such as Estradiol and 
Triptolide inhibited ganglioside 3 synthase (GD3S) expression in cancer cells, thus causing 
cell death (56, 116). Further, a strong interaction between OSW-1 and GM3 gangliosides in 
melanoma cells has been noted (83).  
In this study, we investigated the effect of OSW-1 on ganglioside expression in melanoma. 
Effect of OSW-1 on the ganglioside synthesis regulatory enzyme, GD3 synthase (GD3S) was 
also examined. Our results indicate that OSW-1 suppresses GD3 synthase gene expression in 
melanoma cells, leading to inhibition of gangliosides, GD3, GD2 and subsequent cell death 
by autophagy. Further, OSW-1 promoted interaction between GD3 and mitochondrial 
VDAC1 in melanoma cells. Significantly, OSW-1 upregulated VDAC1 expression in 
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melanoma, leading to loss of calcium homeostasis and cell death. These OSW-1 induced 
alterations in ganglioside and VDAC1 expression play a critical role in mediating the 
selectivity of OSW-1 to malignant melanoma cells.      
3.2 Results 
3.2.1 Cytotoxic effect of OSW-1 in melanoma 
Previous findings, both from our lab and others, demonstrate that OSW-1 inhibits cell 
viability in multiple tumor cell lines including Leukemia, brain, colorectal, hepatic and 
pancreatic cancers at nanomolar concentrations (59, 69). To investigate the effect of OSW-1 
on melanoma cell proliferation, we first performed an MTT assay with multiple melanoma 
cell lines. As illustrated in figure 3.1, OSW-1 is highly potent in inhibiting melanoma cell 
growth with an average half-maximal inhibitory concentration (IC50) of 0.178 nM. A 
subsequent colony formation assay of WM35 cells treated with increasing concentrations of 
OSW-1 indicated that only 36% of cells formed colonies at a concentration of 0.1 nM, with a 
complete inhibition of colony formation at higher concentrations (figure 3.2 A, B). Because 
many of the metastatic melanoma cells did not form colonies on 6-well plates, we adapted 
the MTT assay for long term (figure 3.2 C, D). Melanoma cells were incubated in log-scale 
increasing concentrations of OSW-1 for 8 days. MTT assay was performed in these cells to 
elucidate the effect of OSW-1 on cell proliferation (figure 3.2 C). As indicated in figure 3.2 
D, OSW-1 inhibited melanoma cell growth at sub-nanomolar concentrations with an average 
IC50 of 0.058 nM.       
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Figure 3.1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Effect of OSW-1 on melanoma cell viability 
(A) Melanoma cells were treated with log-scale serial diluted concentrations of OSW-1 for 
72 h, and the antiproliferative effect was determined by performing the MTT assay. The cell 
viability curves were plotted. Each data point represents mean ± SEM of three independent 
measurements. (B) The 50% cell inhibitory concentration (IC50) ± SEM for each cell line is 
indicated. 
Cell line IC50 value 
 (nM) 
Mean IC50 ± SEM 
(nM) 
A375P 0.164 ± 0.045  
 
 
 
 
 
 
0.178 ± 0.043  
A375SM 0.105 ± 0.024 
HS294T 0.027 ± 0.007 
MEL624 0.072 ± 0.010 
SK-MEL-2 0.421±0.218 
UCSD-354L  0.218 ± 0.050 
WM35 0.156 ± 0.024 
WM46 0.097 ± 0.001 
MEWO 0.343 ± 0.068 
A 
B 
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Figure 3.2: OSW-1 inhibits colony formation in melanoma cells. 
(A) and (B) WM35 cells treated with 0.1, 0.3 and 1 nM OSW-1 for 2 weeks were fixed, 
stained with Giemsa and the number of colonies formed were counted. **** denotes p < 
0.0001. (C) Melanoma cells were treated with log-scale serial diluted concentrations of 
OSW-1 for 8 days, and the antiproliferative effect of OSW-1 was determined by performing 
the MTT assay. The cell viability curves were plotted. Each data point represents mean ± 
SEM of three independent measurements. (D) The 50% cell inhibitory concentration (IC50) 
of each cell line in the long-term MTT assay is indicated.  
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Figure 3.3:  
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Effect of OSW-1 on mitochondrial membrane potential (∆Ψm) in melanoma 
cells. 
Melanoma cells were treated with either DMSO control or 1 nM OSW-1 for 72 h and the 
effect of OSW-1 on mitochondrial membrane potential was determined by rhodamine 123 
staining and flow cytometric analysis. OSW-1 induced collapse of membrane potential in 
melanoma cells with an average DMSO vs. OSW-1 p-value = 0.007. **** denotes p < 
0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05. 
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Mitochondrial dysfunction has been implicated in cell death signaling in cells. 
Maintenance of proper mitochondrial membrane potential (∆Ψm) is required for cellular 
homeostasis and normal functioning of cells as it drives ATP synthesis and oxidative 
phosphorylation (117). However, an acute induction of mitochondrial membrane 
permeabilization (MMP) due to calcium overload, oxidative stress, inhibitors such as 
etoposide, arsenite, lonidamine etc. can lead to cell death (118-122). Hence we sought to 
investigate the effect of OSW-1 on mitochondrial transmembrane potential (∆Ψm) across a 
panel of eleven melanoma cell lines (figure 3.3). OSW-1 caused an average decrease in 
mitochondrial membrane potential in melanoma cells by 48%, as compared to the DMSO 
treated control cells (control vs. OSW-1, p-value = 0.007, n = 11). Interestingly, SK-MEL-2 
cells, which have a slightly higher IC50 (0.421 nM, figure 3.1 B) compared to other 
melanoma cells, also exhibited decreased sensitivity to OSW-1 in the mitochondrial 
membrane potential measurement assay, thus pointing towards the heterogeneity of drug 
response to OSW-1 in melanomas.  
3.2.2 OSW-1 triggered cell death in melanoma is associated with autophagy 
Autophagy is an evolutionarily conserved lysosomal degradation pathway that is 
essential for cellular homeostasis and response to stress conditions (123, 124). Previous 
studies have classified autophagy as a non-apoptotic cell death characterized by enhanced 
autophagic flux and accumulation of autophagic vacuoles in cells (125, 126). Transmission 
electron microscopy results showed formation of numerous autophagic vacuoles in WM35 
cells treated with OSW-1 (figure 3.4 A). This autophagic vacuole formation increased with 
time with about a 9- and 21-fold increase in the observed number of autophagic vacuole per 
cell at 24 h and 48 h of 1 nM OSW-1 treatment (figure 3.4 B). The autophagosome-
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associated lipidated form of LC3B (LC3B-II) can be differentiated from the cytosolic free 
isoform (LC3B-I) by immunoblotting (127). Consistent with the morphological findings, a 
time dependent increased expression of the lipidated LC3B (LC3B-II) isoform was observed 
in cells treated with OSW-1 (figure 3.5).  
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Figure 3.4:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: OSW-1 promotes autophagic vacuole formation in melanoma cells. 
(A) Transmission electron microscopy images of WM35 cells treated with 1 nM OSW-1 for 
24 h and 48 h. The black arrows indicate the autophagic vacuole formation induced by OSW-
1. (B) The number of autophagic vacuoles formed per cells for each samples were counted 
and the mean ± SEM of three independent measurements are plotted as bar graphs. ** 
denotes p < 0.01. 
A 
B 
DMSO OSW-1   48 h OSW-1   24 h 
** 
** 
 40 
 
 Figure 3.5:  
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Effect of OSW-1 on the autophagy marker, LC3B expression. 
WM35 cells were treated with 1 nM OSW-1 for 12, 24 and 48 h and immunoblotting was 
performed to examine lipidation of the autophagy marker protein LC3B. 
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Figure 3.6: Autophagy induction is crucial to cell death induction by OSW
(A) WT and Atg5-/- MEF cells were treated with varying concentrations of OSW
and the cytotoxic effect was determined by the MTT assay, as described in materials and 
methods. Percent cell survival corresponding to each OSW
WM35 cells preincubated with 1mM 3
48 h. Effect of OSW-1 ± 3-MA combination on cell viability was evaluated by annexin
analysis and is represented as bar graphs normalized to the DMSO control.
0.01. 
A 
B 
-1 concentration was plotted. (B) 
-methyl adenine for 1 h were treated 1nM OSW
** 
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The autophagy related protein 5, Atg5, is an essential autophagy protein, which 
conjugates with Atg12 to form a multimeric structure that is crucial for autophagosome 
formation (128, 129). Hence, we employed Atg5 knock out (Atg5-/-) MEF cells to 
characterize the role of autophagy in mediating the cell inhibitory effect of OSW-1. MTT 
results from WT and Atg5-/- MEF cells treated with log-scale incremental concentrations of 
OSW-1 for 72 h demonstrated that the Atg5-/- cells exhibited decreased sensitivity to OSW-1 
(figure 3.6 A). 1 nM OSW-1 effectively inhibited cell viability by approximately 80% in 
MEF WT cells while an approximate 75% of MEF Atg5-/- cells were still viable at this 
concentration. Nevertheless, higher concentrations of OSW-1 killed both MEF WT and 
Atg5-/- cells. In complementation to this observation, the autophagy inhibitor, 3-Methyl 
Adenine (3-MA), partially rescued WM35 cells from the cytotoxic effect of OSW-1 (130, 
131). As shown in figure 3.6 B, OSW-1 treatment for 48 h abolished cell survival to 30%. 
However, combination of OSW-1 with 3-MA reversed cell survival to 60.76%. These 
findings not only delineate the significance of autophagy in OSW-1 induced elimination of 
melanoma cells, but also allude to the fact that there might also be simultaneous alternate cell 
death mechanisms facilitating OSW-1’s activity.  
Interestingly, combination of OSW-1 with the lysosomotrophic agent Chloroquine led 
to rapid apoptotic cell death. Chloroquine inhibits late phase autophagy by preventing the 
fusion of the autophagosomes to lysosomes (132). Because of this mechanism of action, 
chloroquine has found utility in sensitizing multiple cancer cells including hepatocellular and 
cervical cancers to radiation and drugs like cisplatin and oxaliplatin (133, 134). Combination 
of OSW-1 with chloroquine produced approximately 48% (normalized to control) increased 
cell death in WM35 cells as compared to OSW-1 treatment alone (figure 3.7 A). To evaluate 
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the type of drug interaction, we performed combination index (CI) analysis of different 
combination regimens of OSW-1  (0.1, 0.3 and 1 nM, 48 h) and chloroquine (5, 10 and 20 
µM, 48 h) in melanoma cells (135, 136). As described in figure 3.7 B, the combination 
regimen between OSW-1 and chloroquine was synergistic (CI <1) for seven of the nine 
combination treatments with 1 nM OSW-1 and 5 µM chloroquine showing the strongest 
effect (CI = 0.111). Interestingly, an antagonistic combination effect (CI >1) was observed 
on combining 20 µM chloroquine with 1 nM OSW-1 in WM35 cells.  
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Figure 3.7:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chloroquine 
(µM) 
OSW-1 
(nM) 
Combination 
Index (CI) 
5 0.1 1.067 
5 0.3 0.494 
5 1 0.111 
10 0.1 0.768 
10 0.3 0.533 
10 1 0.184 
20 0.1 0.714 
20 0.3 1.039 
20 1 1.349 
56% 10% 
93% 96% 
DMSO 10 µM CQ 
1nM OSW-1 OSW-1 + CQ 
A 
B 
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Figure 3.7: Cytotoxic effect of OSW-1 ± Chloroquine drug combination in melanoma 
cells.  
(A) 1 nM OSW-1 was added to WM35 cells pretreated with 10 µM chloroquine for 20 min. 
After 72 h incubation, cell viability was determined by annexin v/PI staining and flow 
cytometric analysis. The percentage of viable cells (negative for annexin V and PI) is 
indicated. (B) WM35 cells were treated with the indicated concentrations of OSW-1 ± CQ 
drug combination for 48 h and combination index analysis was performed using Compusyn 
software.  The combination index (CI) values were computed. The following quantitative 
definitions, based on the Chou-Talalay theorem, were employed to define combination 
effect: CI < 1 - synergism, CI = 1 - additive effect and CI > 1 - antagonism. 
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Figure 3.8:  
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Figure 3.8: Cytotoxic effect of OSW-1 ± Rapamycin drug combination in melanoma 
cells.  
(A) A375SM cells were treated with 1 nM OSW-1 ± 100 nM Rapamycin for 48 h and the 
effect on mitochondrial membrane potential was determined by rhodamine 123 analysis. (B) 
Bar graphs represent the mitochondrial membrane potential changes induced by A375SM 
and WM35 cells treated with 1 nM OSW-1 ± 100 nM Rapamycin for 48 h. (C) Effect of  1 
nM OSW-1 ± 100 nM Rapamycin 48 h treatment on the viability of A375SM and WM35 
cells was determined by annexin-V/PI analysis and is represented as bar graphs. ** denotes p 
< 0.01. 
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The mammalian target of rapamycin (mTOR) serves as a central regulator of 
autophagy by inhibiting phosphorylation of the autophagy proteins Atg13 and Unc51-like 
kinase (ULK), and preventing autophagosome formation (137-139). The antibiotic, 
Rapamycin inhibits mTOR thus acting as a potent autophagy inducer in multiple cell lines 
(140, 141). In our study, we found that rapamycin ameliorated the cytotoxic effect of OSW-1 
in melanoma cells (figure 3.8). A375SM and WM35 cells were co-treated with 1 nM OSW-1 
and 100 nM rapamycin for 48 h and the effect on mitochondrial transmembrane potential 
(∆Ψm) and cell death was assessed through flow cytometry by staning the cells with 
rhodamine 123 (figure 3.8 A, B) and annexin-FITC/PI (figure 3.8 C). As illustrated in figure 
3.8 A and B, rapamycin partially reversed the mitochondrial membrane permeabilization 
induced by OSW-1. 1 nM OSW-1 caused a loss of membrane potential by 56.33% and 
60.3% in A375SM and WM35 cells. However, rapamycin + OSW-1 treatment led to a 
reversal of this effect to 16.2% and 34.07% in A375SM and WM35 cells. Similarly, 
rapamycin also partially rescued A375SM and WM35 cells from the antiproliferation effect 
of OSW-1 (figure 3.8 C). These drug combination (OSW ± chloroquine/rapamycin) results 
elucidate the dual roles of autophagy in maintaining cellular homeostasis wherein though 
autophagy might start-off as a cell protective mechanism, sustained autophagy mediated by 
OSW-1 leads to melanoma cell killing. 
3.2.3 Normal melanocytes are resistant to OSW-1 induced cytotoxicity  
The promising antineoplastic effect of OSW-1 against melanoma cells led us to 
examine the effect of this compound in normal melanocytes. As shown in figure 3.9, OSW-
1induced a time dependent loss of mitochondrial potential in A375SM melanoma cells, while 
normal melanocytes were resistant to this effect of OSW-1. 1 nM OSW-1, 72 h treatment, did 
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not trigger significant mitochondrial membrane potential loss in normal melanocytes (17.4%; 
figure 3.9 A) compared to melanoma cells (n = 11, 52%; figure 3.3).   
 
Figure 3.9:  
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Effect of OSW-1 on mitochondrial membrane potential in normal 
melanocytes vs. melanoma cells. 
Mitochondrial membrane potential in normal melanocytes and A375SM cells treated with 1 
nM OSW-1 for 48 h and 72 h was evaluated by rhodamine 123 staining as described in 
materials and methods.  
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Figure 3.10: 
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Figure 3.10: Selective killing of melanoma cells by OSW-1. 
(A) Melanoma cells and normal melanocytes were treated with 0.5, 1 and 2 nM OSW-1 for 
72 h and the effect on cell viability was determined by annexin V/PI analysis. Each data 
point represents the mean of three independent measurements. (B) Comparison of viability of 
A375SM cells and normal melanocytes treated with 1 nM OSW-1 for indicated time 
duration. Cell viability was determined by annexin V-FITC/PI staining. The numbers 
indicate the percentage of viable cells (negative for annexin V and PI).   
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We designed a follow-up time course experiment with 1 nM OSW-1 and performed 
an annexin-V/PI staining assay to determine the effect of OSW-1 on cell death. Normal 
melanocytes were resistant to the cytotoxic effect of OSW-1; 97.04% of normal melanocytes 
were still viable after OSW-1 treatment for 96 h as compared to only 3.9% of A375SM 
melanoma cells (figure 3.10 B). Figure 3.10 A represents the cell inhibitory effect of OSW-1 
against multiple melanoma cell lines (n = 7) and normal melanocytes treated with increasing 
concentrations of OSW-1 for 72 h. The scatter plot while delineating the heterogeneous 
response of melanoma cells to OSW-1, also highlights the therapeutic selectivity of OSW-1 
towards melanoma cells (1 nM OSW-1, average melanoma (n = 7) cell viability = 46.88%) 
with limited toxicity to normal melanocytes (1 nM OSW-1, average cell viability = 93.30%).      
3.2.4 OSW-1 inhibits ganglioside GD3/GD2 expression in melanoma cells 
Recent studies by Kwon et al and Battula et al demonstrated that Triptolide, a 
diterpenoid triepoxide, inhibits ganglioside GD3 and GD2 expression by repressing GD3 
synthase (ST8Sia I) expression (24, 56). Since Triptolide bears structural similarity to OSW-
1, we hypothesized that OSW-1 would inhibit gangliosides GD3 and GD2 expression by 
suppressing GD3 synthase (GD3S) expression. To test this hypothesis we assessed alterations 
in ganglioside expression after OSW-1 treatment of melanoma cells (figure 3.11). Flow 
cytometric analysis of WM35 and A375SM treated with OSW-1 and stained with ganglioside 
antibodies revealed that OSW-1 caused a moderate decrease in ganglioside GD3 (figure 3.11 
A, B) and a more striking inhibition of GD2 (figure 3.11 C, D). This inhibition of ganglioside 
expression was time dependent, with GD2 inhibition starting as early as 3 h post OSW-1 
treatment (figure 3.11 C, D). Figure 3.12 depicts the effect of OSW-1 on GD2 expression 
against a panel of melanoma cell lines. On average, a 24 h OSW-1 treatment of melanoma 
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cells reduced GD2 expression to 66.86% (DMSO vs. OSW-1, p-value =  0.0029). Further, 
this GD3 and GD2 inhibition correlated with an accumulation of ganglioside GM3 (figure 
3.11 E, F). A 24 h 1nM OSW-1 treatment led to an increased expression of ganglioside GM3 
by 178.2% and 127.4% in A375SM and WM35 melanoma cells (figure 3.11 F).  
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Figure 3.11:  
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Figure 3.11: Effect of OSW-1 on ganglioside expression in melanoma. 
(A), (C) and (E) A75SM cells treated with 1 nM OSW-1 for the indicated time points were 
analyzed for ganglioside GD3, GD2 and GM3 expression by flow cytometry as described in 
materials and methods. (B), (D) and (F) GD3, GD2 and GM3 ganglioside expression in 
A375SM and WM35 cells treated with 1 nM OSW-1 for the indicated time points was 
determined by flow cytometric measurements. Bar graphs represent mean ± SEM of percent 
ganglioside (GD3/GD2/GM3) inhibition from three independent experimental measurements. 
** denotes p < 0.01 and * denotes p< 0.05.  
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Figure 3.12:  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Effect of OSW-1 on ganglioside GD2 expression in melanoma cells. 
Melanoma cells were treated with either DMSO control or 1 nM OSW-1 for 24 h and the 
effect of OSW-1 on ganglioside GD2 expression was quantified. Bar graphs represent mean 
± SEM from three independent experiments. OSW-1 induced inhibited GD2 expression in 
melanoma cells with an average DMSO vs. OSW-1 p-value = 0.0029. **** denotes p < 
0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05.  
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Figure 3.13: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: OSW-1 represses gene expression of GD3S, FASN and HMGCR enzymes. 
Real time PCR was performed in A375SM cells treated with 1 nM OSW-1 for 12h and 24 h. 
The effect of OSW-1 on the expression of GD3S, FASN and HMGCR genes was 
determined. Each experiment was performed with three technical replicates. The bar graphs 
represent the mean result from three biological replicates. **** denotes p < 0.0001, *** 
denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05.  
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Figure 3.14: 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Effect of OSW-1 on GD2 Synthase gene expression. 
Real time PCR was performed in A375SM cells treated with 1 nM OSW-1 for 12h and 24 h. 
The effect of OSW-1 on the expression of GD2S gene was determined. * denotes p < 0.05. 
 
 
 
 
 
 
 
 
 
* 
 59 
 
Figure 3.15: 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Schematics of OSW-1 mediated modulation of ganglioside expression. 
The model summarizes the effect of OSW-1 on ganglioside expression. OSW-1 suppresses 
the expression of GD3 synthase gene leading to inhibition of GD3, GD2 and accumulation of 
ganglioside GM3.  
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Figure 3.16:  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Combination of OSW-1 with Triptolide partially reverses the OSW-1 
induced mitochondrial membrane potential loss in melanoma. 
A375SM cells were treated with 1nM OSW-1 ± 20 nM Triptolide for 48 h and the effect on 
mitochondrial membrane potential was determined by rhodamine 123 analyses.  
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As shown in figure 3.15, ganglioside GD3 is produced from its precursor GM3 
through a reaction catalyzed the enzyme GD3 synthase. Results from real-time PCR, 
performed to ascertain the effect of OSW-1 on GD3S mRNA expression, indicated that 
OSW-1 represses GD3S gene expression in a time dependent fashion (figure 3.13). 
Expression of GD2 synthase (GD2S) gene though initially suppressed by OSW-1, increased 
after 24 h of OSW-1 treatment (figure 3.14). Interestingly, combination of Triptolide with 
OSW-1 partially reversed the mitochondrial membrane collapse induced by OSW-1 (figure 
3.16), suggesting that both OSW-1 and Triptolide elicit their antiproliferation activity 
probably by acting on similar cellular targets. Yamauchi et al., (2011) demonstrated that 
elevated GD3 levels correlated with increased expression of key lipogenic enzymes in 
melanoma cell lines (10). Based on this, we hypothesized that inhibition of GD3 by OSW-1 
would lead to suppressed expression of enzymes mediating the lipogenesis pathway. 
Accordingly, 1 nM OSW-1 treatment for 24 h caused a 3.24- and 5.73-fold decrease in fatty 
acid Synthase (FASN) and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) 
expression in melanoma cells (figure 3.13). Thus we conclude that OSW-1 suppresses GD3S 
expression in melanoma leading to inhibition of gangliosides GD3 and GD2 and the 
downstream lipogenic enzymes, FASN and HMGCR. 
3.2.5 OSW-1 promotes interaction of ganglioside GD3 with VDAC1 in the mitochondria  
Raft-like microdomains on the mitochondrial membrane are enriched with 
gangliosides GD3 and GM3, and act as potential catalytic sites for autophagic and apoptotic 
reactions (60, 142, 143). Activation of cell death receptor signaling via CD95/Fas or tumor 
necrosis factor-α (TNF-α) promotes intracellular redistribution and vesicular transport of 
ganglioside GD3 to mitochondria, wherein GD3 promotes apoptosis by acting on the 
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mitochondrial transition pore and causing cytochrome c release (144-146). Garofalo et al. 
(2005) also demonstrated that during CD95/Fas mediated apoptosis GD3 interacts with 
voltage dependent anion channel 1 (VDAC1) and the fission protein hFis1 in the 
mitochondrial lipid microdomains of lymphoblastoid CEM cells (143). Furthermore, prior 
results from our lab suggest that OSW-1 has a mitochondrial mechanism of action (59). 
Hence we investigated the effect of OSW-1 on mitochondrial targeting of GD3. To 
characterize the distribution of GD3 and VDAC1 in the membrane microdomains, we 
isolated lipid rafts fractions by performing a linear 5-80% sucrose gradient of the DMSO 
control and OSW-1 treated A375SM cell lysates (figure 3.17). Majority of the lipid raft 
resident protein caveolin-1 was recovered in fractions 2, 3 and 4. Ganglioside GD3 was also 
concentrated in fractions 2, 3 (highest expression) and 4 of the DMSO control sample. 
Nevertheless, OSW-1 administration promoted redistribution of GD3 expression to fractions 
2, 3, 4, and 5. More significantly, OSW-1 stimulated elevated VDAC1 expression in the 
corresponding fractions (2, 3, 4, and 5) whereas a diminished expression of VDAC1 was 
observed in these caveolin enriched lipid raft fractions of the control sample. To confirm 
these results, A375SM cells were treated with OSW-1 for 24 h and the cellular co-
localization of VDAC1 and GD3 was examined by confocal microscopy. As shown in figure 
3.18, OSW-1 potentiated increased co-localization of ganglioside GD3 with VDAC1in the 
mitochondria, thus corroborating previous findings that cell death signaling triggered 
intracellular redistribution and mitochondrial trafficking of GD3 (143, 145).  
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Figure 3.17: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17: Effect of OSW-1 on GD3 and VDAC1 co-expression in lipid rafts. 
Glycosphingolipid enriched microdomain/lipid raft fractions from DMSO and 1 nM OSW-1 
24 h treated A375SM samples were prepared and equal amounts of the fractions were 
subjected to an immunoblot for VDAC1 and the lipid raft resident protein caveolin-1. 
Simultaneously, a dot blot was performed to determine GD3 expression in the lipid raft 
fractions. OSW-1 potentiates redistribution of GD3 and VDAC1 expression in lipid rafts. 
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Figure 3.18: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: OSW-1 promotes co-localization of VDAC1 with ganglioside GD3. 
A375SM cells were grown on coverslips and treated with 1 nM OSW-1 for 24 h. The cells 
were stained with VDAC1 and GD3 antibodies as per the procedure described in materials 
and methods and confocal microscopic images were taken. 
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Figure 3.19: 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Correlation between OSW-1 induced mitochondrial membrane potential 
loss and ganglioside GD2 inhibition. 
The fold change in mitochondrial membrane potential induced by OSW-1 was plotted as a 
function of fold change in GD2 expression. Linear regression analysis was performed and a 
Pearson’s correlation coefficient of 0.7100 with a p value of 0.0144 was obtained. 
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 The relationship between inhibition of ganglioside GD3/GD2 expression and 
sensitivity of melanoma cells to OSW-1 was evaluated quantitatively by plotting fold change 
in mitochondrial membrane potential (∆Ψm) as a function of ganglioside GD2 expression 
change upon OSW-1 treatment (figure 3.19). Our results indicate that there was a positive 
correlation between these two factors (r = 0.7100, p = 0.0144), thus suggesting that 
ganglioside inhibition sensitizes melanoma cells to the cytotoxic effect of OSW-1.  
3.2.6 OSW-1 eliminates melanoma cells through mitochondrial VDAC1 dependent 
mechanisms 
OSW-1 stimulated increased interaction between GD3 and mitochondrial VDAC1 
(figure 3.18). VDAC1 plays an important role in the transport of adenine nucelotides, Ca2+, 
and other ions and metabolites across the mitochondria in addition to mediating apoptotic 
and autophagic signaling in mitochondria (147-152). Therefore, we studied the role of 
VDAC1 in OSW-1 induced cell death. Towards this end, we first examined melanoma cells 
for VDAC1 expression after OSW-1 treatment. VDAC1 expression was markedly increased 
by OSW-1 in A375SM and WM35 cells but was slightly decreased in normal melanocytes 
which were resistant to OSW-1 (figure 3.20 A, B). On average, OSW-1 incubation for 36 h 
triggered a 4.8- and 3.2-fold increase in VDAC1 expression in A375SM and WM35 cells 
while a 1.7-fold decrease was observed in normal melanocytes (figure 3.20 C). Further, the 
de novo protein synthesis inhibitor, cycloheximide reduced this VDAC1 elevation in 
melanoma cells, indicating that OSW-1 caused a translational upregulation of VDAC1 
(figure 3.21). Further, cycloheximide treatment for 2 h resulted in inhibition of 50% of 
VDAC1 expression compared to the untreated control suggesting that the half-life of VDAC1 
was around 2 h (figure 3.21). Significantly, Triptolide, which represses GD3 synthase, also 
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led to VDAC1 induction by 1.4-fold in A375SM cells (figure 3.22). Collectively, these data 
indicate that GD3S inhibition by OSW-1 may lead to VDAC1 activation and this VDAC1 
increase positively correlates with cellular sensitivity to OSW-1 in melanoma cells. 
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Figure 3.20: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: OSW-1 induces VDAC1 upregulation in melanoma cells. 
Immunoblots of A375SM, WM35 and NHEM cells treated with 1 nM OSW-1 for 0.5, 12, 24 
and 36 h (A) and 24 h only (B). (C) Densitometric measurement of the VDAC1 band 
intensity relative to β-actin is shown. The bar graphs represent mean ± SEM of normalized 
VDAC1 expression from three independent immunoblot assessments.  * denotes p < 0.05. 
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Figure 3.21: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Effect of cycloheximide on OSW-1 induced VDAC1 upregulation in 
melanoma cells.  
A375SM cells were pre-incubated in 1 nM OSW-1 for 24 h, followed by 2 µM 
cycloheximide treatments for 0.5, 1, 2, 4 and 8 h. Simultaneously A375SM cells were treated 
with 2 µM cycloheximide as a single agent for 0.5, 1, 2, 4 and 8 h. Immunoblot was 
performed to examine changes in VDAC1 expression. 
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Figure 3.22:  
 
 
 
 
 
 
 
 
Figure 3.22: Effect of Triptolide on VDAC1 expression in melanoma cells. 
A375SM cells treated with 20 nM Triptolide for 24 h and VDAC1 protein expression was 
detected by immunoblot analysis. 
 
 
 
 
 
 
 
 
 
 
 
VDAC1 
β-Actin 
DMSO 
T
P
L 
 1      1.44 
 71 
 
Figure 3.23: 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: Induction of mitochondrial superoxide release by OSW-1 in melanoma. 
A375SM and WM35 cells treated with 1 nM OSW-1 for the indicated time points were 
probed with the fluorescent mitochondrial superoxide indicator, mitosox red and the 
mitochondrial superoxide release was determined by flow cytometric analysis. **** denotes 
p < 0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p < 0.05.  
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Figure 3.24: 
 
 
 
 
 
 
 
 
 
Figure 3.24: OSW-1 induces cytosolic calcium elevation in melanoma cells. 
A375SM and WM35 cells were treated with OSW-1 for the indicated time points and the 
changes in cytosolic calcium levels were quantified using the calcium green fluorescent 
probe. (A) A representative histogram of the calcium changes induced by OSW-1. (B) Bar 
graph indicates the mean ± SEM of percent calcium increase in A375SM and WM35 cells 
from three independent experiments. * denotes p < 0.05. 
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Apart from VDAC1 induction, OSW-1 also stimulated mitochondrial superoxide 
release (figure 3.23) and increase of cytosolic calcium (figure 3.24) in a time-dependent 
fashion. The immunosuppressant cyclosporin A (CsA) inhibits cyclophilin D, a 
mitochondrial matrix peptidyl-prolyl isomerase known to modulate opening of the 
mitochondrial transition pore (153, 154). In addition, CsA, through pharmacological 
inhibition of the serine/threonine phosphatase, calcineurin, promotes cell death in melanoma 
and other solid tumors (155-157). Therefore it was conceivable to evaluate the effect of CsA 
on OSW-1 mediated cytotoxicity in melanoma. Pre-incubation of WM35 cells with CsA 
increased the antiproliferation effect of 0.3 nM OSW-1 from 22.0% to 73.3% (figure 3.25 A). 
Similarly, combination of OSW-1 with CsA caused a 10.25-fold decrease in mitochondrial 
membrane potential as compared to the DMSO control while 0.3 nM OSW-1 single agent 
treatment caused a slight increase by 1.8 fold (figure 3.25 B). Interestingly, CsA+OSW-1 
incubation for 24h promoted incremental VDAC1 expression in WM35 cells (figure 3.26 A). 
This VDAC1 induction by CsA+OSW-1 combination was slightly higher than the effect of 
OSW-1 as a single agent, while CsA by itself did not cause affect VDAC1. Further, pre-
incubation of CsA with OSW-1 potentiated higher cytosolic calcium release when compared 
to the effect of CsA/OSW-1 as a single agent (figure 3.26 B, C). The cytosolic Ca2+ levels in 
WM35 cells treated with CsA+OSW-1 for 24 h increased to 229.5% while OSW-1 or CsA 
alone caused Ca2+ elevation to 200.7% and 156.2% respectively (figure 3.26 C). These 
results, together with our previous findings, demonstrate that the mitochondrial outer 
membrane protein, VDAC1 and other mitochondria dependent mechanisms including 
superoxide release and Ca2+ elevation play an important in leukemia cells executing the 
anticancer activity of OSW-1 (58, 59). 
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Figure 3.25: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: Combination of OSW-1 with Cyclosporin A (CsA) causes elevated cell 
death effect in melanoma cells. 
(A) Melanoma cells treated with the indicated concentrations of OSW-1 and CsA for 48 h, 
were analyzed for cell death by annexin V/PI staining. The numbers denote percent cell 
viability (annexin V negative/PI negative) for each sample. (B) Mitochondrial membrane 
potential loss in cells treated with 0.3 nM OSW-1 ± 10 µM CsA for 48 h was detected by 
rhodamine 123 staining.  
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Figure 3.26: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: Effect of OSW-1 and Cyclosporin A (CsA) drug combination on VDAC1 
expression and calcium homeostasis. 
(A) Immunoblot was performed in WM35 cells treated with 1 nM OSW-1 ± 2 µM CsA for 
24 h. (B) and (C) Cytosolic calcium changes in A375SM and WM35 cells treated with 1 nM 
OSW-1 ± 3 µM CsA for 24 h was determined. Figure (B) denotes a representative histogram 
of the calcium changes induced by OSW-1 in A375SM cells. 
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Figure 3.27: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: OSW-1 treatment causes elevated expression of phosphorylated ERK1/2 in 
melanoma.  
(A) A375SM and WM35 cells were treated with 1 nM OSW-1 for the indicated time points 
and immunoblot was performed for total and phosphorylated-ERK1/2 proteins. (B) and (C) 
A375SM cells pre-incubated in 5 µM U0126 for 1 h were treated with 1 nM OSW-1 for 48 h. 
Mitochondrial membrane potential and cell viability were determined by rhodamine 123 (B) 
and annexin-V/PI analysis (C). Bar graphs represent the mean ± SEM measurements of three 
individual experiments. 
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Tringali et al. identified that ganglioside GM3 accumulation in K562 cells drove cell 
differentiation towards megakaryocytes and increased ERK1/2 phosphorylation through 
protein kinase C dependent cell signaling (158). Recent reports also indicate a positive 
correlation between GM3 accumulation and ERK1/2 activation in the brain astrocytes from a 
sandhoff disease mouse model (159). Further, overexpression of GD3 synthase gene 
inhibited PDGF-mediated ERK1/2 phosphorylation, thereby modulating cell proliferation 
and cell cycle progression in vascular smooth muscle cells (VSMC) cells (160). OSW-1 
induced a time dependent increase in phospho-ERK1/2 expression in A375SM and WM35 
cells (figure 3.27 A). We hypothesized that if ERK1/2 activation was crucial to the antitumor 
activity of OSW-1, then pre-incubation of melanoma cells with the MEK1/2 inhibitor, U0126 
will rescue the cells from the cytotoxic effect of OSW-1. U0126 did not reverse the 
mitochondrial membrane potential loss triggered by OSW-1 (figure 3.27 B). Moreover, 
combination of OSW-1 with U0126 led to incremental inhibition of cell viability in 
melanoma cells (figure 3.27 C). U0126+OSW-1 combination produced 31.70% increased 
cell death in A375SM cells than OSW-1 single agent treatment (figure 3.27 C). Based on our 
results, we conclude that ERK1/2 activation is not a critical mechanism in mediating OSW-
1’s anticancer effect, and is plausibly a downstream effect of the modulation of ganglioside 
expression pattern by OSW-1. 
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3.2.7 VDAC1 is a critical player in mediating the cytotoxic effect of OSW-1 
To determine if VDAC1 induction is of functional significance to OSW-1 induced 
cytotoxicity, we used VDAC1 knock out (VDAC1-/-) mouse embryonic fibroblast (MEF) 
cells. We performed a72 h MTT assay with MEF WT and VDAC1-/- cells treated with log 
scale serial diluted concentrations of OSW-1 (figure 3.28 A).  MEF VDAC1-/- cells were 
significantly resistant to OSW-1 with a half-maximal inhibitory concentration approximately 
44 times higher than the WT MEF cells (figure 3.28 A). Likewise MEF VDAC1-/- cells were 
resistant to the loss of mitochondrial membrane potential induced by OSW-1, whereas 
incubation of MEF WT cells with 1, 3 and 10 nM OSW-1 incubation for 72 h resulted a 
mitochondrial collapse to 41.85%, 29.50% and 16.85% respectively (figure 3.28 B).  
 To characterize the role of VDAC1 in melanoma cell sensitivity to OSW-1, we 
performed siRNA mediated knock down of VDAC1 expression in A375SM cells (figure 3.29 
A). As shown in figure 3.29 B and C, OSW-1 induced mitochondrial membrane potential 
(∆Ψm) loss was substantially attenuated in siVDAC1 transfected A375SM cells. Further, a 48 
h MTT assay in scrambled control and siVDAC1 transfected A375SM cells demonstrated 
that the siVDAC1 cells were 4-times less sensitive to OSW-1 compared to the scrambled 
control cells (figure 3.29 D). Interestingly the degree of resistance to OSW-1 observed in 
siVDAC1 transfected A375SM cells was lower than the MEF VDAC1-/- cells ((figure 3.29 
D, figure 3.28 A). This may be because of the transient nature of VDAC1 knockdown and 
the need for A375SM cells to get acclimatized to this down regulation of VDAC1. Also, pre-
incubation of A375SM cells with the VDAC inhibitor, DIDS, did not rescue the cells from 
GD2 ganglioside inhibition triggered by OSW-1 (figure 3.30), thus indicating that VDAC1 
does not have a regulatory function in the ganglioside expression change stimulated by 
  
OSW-1. Collectively, our data strongly suggest that VDAC1 plays a crucial role in mediating 
OSW-1 induced cytotoxicity in melanoma cells.
Figure 3.28: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: MEF VDAC1-
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Mitochondrial membrane potential change induced by 72 h treatment of 1, 3 and 10 nM 
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Figure 3.29: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.29: Down regulation of VDAC1 in A375SM cells confers resistance to OSW
(A) Immunoblot for VDAC1 in A375SM cells transfected with siVDAC1 and negative 
control. (B) and (C) Mitochondrial membrane potential analysis of siVDAC1 and negative 
control transfected A375SM cells treated with 1 nM OSW
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Figure 3.30: 
                
 
                          
                          
Figure 3.30: Combination of OSW-1 with the VDAC1 inhibitor, DIDS, indicates that 
VDAC1 does not regulate ganglioside expression.  
A375SM cells were treated with 1 nM OSW-1 ± 200 µM DIDS for 24 h and ganglioside 
GD2 expression was determined by flow cytometry.   
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3.2.8 Characterization of the mechanisms underlying the therapeutic selectivity of 
OSW-1 
Therapeutic selectivity is a major concern while developing an anticancer agent. Our early 
findings indicate that OSW-1 is highly selective towards melanoma cells with limited 
toxicity in normal melanocytes (figure 3.9, 3.10). Hence we sought to delineate the 
mechanisms causal this selectivity of OSW-1 for melanoma cells. Towards this end, we first 
cultured WM35 cells in RPMI media supplemented with increasing concentrations of OSW-
1 for a period of 2-3 months to generate “OSW-1 resistant” WM35 cells (WM35R). An 
aliquot of these cells were then returned back to RPMI media without OSW-1 (WM35 drug 
withdrawn, WM35DW). These WM35DW cells continued to display the OSW-1 resistant 
phenotype, despite being cultured in non-OSW-1 growth media, and thus represent the truly 
OSW-1 resistant melanoma cells. A preliminary MTT assay indicated that WM35DW and 
WM35R cells were about 680 and 332 times more resistant to OSW-1 than the parental 
WM35 cells (figure 3.31). Henceforth, we used this WM35 vs. WM35DW vs. WM35R cell 
model for our further study.  
 
 
 
 
 
 
 
 
  
Figure 3.31: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: The OSW-1 resistant WM35 cell model
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Figure 3.32: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: OSW-1 resistant WM35 DW cells have a decreased ganglioside GD3/GD2 
expression profile compared to the parental WM35 melanoma cells.  
The basal GD3 (A) and GD2 (B) expression in WM35, WM35 DW and WM35 R cells was 
determined by flow cytometry as described in materials and methods. * denotes p < 0.05.  
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Figure 3.33: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: OSW-1 resistant WM35 DW cells have an altered free radical expression 
profile compared to the parental WM35 melanoma cells.  
(A) Basal mitochondrial superoxide levels were evaluated using the mitosox red fluorescent 
indicator as described in materials and methods. Bar graphs represent mean ±SEM from three 
independent experiments. (B) Basal level expression of reactive oxygen species, superoxides 
and nitric oxide was determined by flow cytometric analysis of cells stained for DCFDA, 
Dihydroethidium and DAF-FM fluorescent probes. * denotes p < 0.05.  
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A comparison of the basal GD3 and GD2 ganglioside expression indicated that 
WM35DW cells have a significantly decreased GD3 (p = 0.08) and GD2 (p = 0.02) 
expression as compared to the parental WM35 cells (figure 3.32 A, B). But no significant 
change in ganglioside GM3 expression between the two cell samples was observed. Further, 
the basal mitochondrial superoxide levels were significantly reduced in WM35DW than the 
parental WM35 cells (figure 3.33 A). This correlated with decreased expression of reactive 
oxygen species, cytosolic superoxides and nitric oxide in the WM35DW vs. WM35 cells 
(figure 3.33 B). Based on these results, we postulate that the basal ganglioside GD3/GD2 
expression profile plays a critical role in governing the response of melanoma cells to the 
antitumor effect of OSW-1.  
To explore other potential markers of sensitivity to OSW-1, we performed reverse 
phase protein array (RPPA) of 217 total- and phospho-proteins (figure 3.34). Of specific 
interest to us were lipogenesis (figure 3.35 A, B), and mitochondria (figure 3.35 A, C) 
signaling proteins, whose expression was statistically significantly different (p < 0.05) 
between WM35 vs. WM35DW vs. WM35 R cells. RPPA analysis results demonstrate that 
VDAC1 (porin), Bcl-2, Mcl-1, GSK3 and PKC-α expression was reduced in WM35DW and 
WM35R compared to the parental WM35 cells (figure 3.35 A, C).  However cyclophilin F 
and phosphorylated NF-κB levels were higher in the resistant cells. Among the lipogenesis 
proteins, fatty acid synthase (FASN) expression was significantly increased, while caveolin-
1, and focal adhesion kinase (FAK) expression was decreased in the WM35DW and WM35R 
resistant cells than the parental WM35 cells (figure 3.35 A, B). Interestingly, expression 
levels of cell survival and proliferation proteins like PI3K, Akt and phospho-MAPK and –
  
MEK was lower in the resistant WM35DW and WM35R cells than the parental WM35 cells 
(figure 3.34).  
Figure 3.34:                                        
 
          
          
 
 
Figure 3.34: Differential protein expression 
Heat map generated based on the RPPA analysis of WM35 vs. WM35 DW vs. WM35 R cells for 
the basal expression of the proteins indicated.
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Figure 3.35: 
              
    
                   
 
 
 
 
 
 
 
Figure 3.35: Differential expression of 
in WM35 vs. WM35 R vs. WM35 DW cells
RPPA analysis was performed in WM35 vs. WM35 DW vs. WM35 R cells. The expression 
of proteins from the lipogensis (figures A, B) and mitochondrial signaling (figure A, C) 
pathways that differed significantly in WM35 vs. WM35 DW vs. WM35 R cells is indicate
as a heat map and bar graphs.       
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3.3 Discussion 
In this study we demonstrated that OSW-1 effectively eliminates melanoma cells by 
causing inhibition of gangliosides GD3/GD2 and upregulation of mitochondrial VDAC1 
leading to autophagic cell death.   
 Burgett et al identified the lipid metabolism proteins, OSBP and ORP4L as cellular 
binding targets of OSW-1(69). Prior findings from our lab demonstrated that OSW-1 
functions by disrupting cellular calcium homeostasis through inhibition of the Na+/Ca2+ 
exchanger 1 (NCX1) leading to apoptotic cell death in leukemia cells (58). More recently, 
Yamada et al., employed a fluorescent analog to investigate the cellular internalization and 
localization of OSW-1 in HeLa cells (82). Microscopic imaging studies revealed that OSW-1 
rapidly internalized and distributed primarily in the intracellular membranes of the 
endoplasmic reticulum (ER) and Golgi apparatus and to a lesser extent in the mitochondria 
(82). Cumulatively, these findings suggest that a novel target for OSW-1 other than 
NCX1/OSBP may exist in these subcellular sites and merits further investigation.   
Gangliosides are constituents of the glycosphingolipid-enriched microdomains (GEM 
or rafts) in the cell membrane, where they play a pivotal role in mediating cell proliferation, 
invasion and adhesion signaling (17, 19). Previous investigations provide evidence that 
ganglioside synthesis occurs intracellularly in the golgi complex and the ‘mitochondria-
associated membrane’ (MAM) compartment of the endoplasmic reticulum through a 
glycosylation process regulated by glycosyltransferases, including GD3 synthase, a resident 
Golgi protein (161, 162). Specifically, the ganglioside GD3 plays a paradigmatic role, 
wherein, in contrast to its cell proliferative function, it also acts as a cell death effector 
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through its intracellular translocation to the mitochondria during stress conditions, leading to 
cytochrome c release, ROS generation and cell killing (143, 144, 146).  
Our results demonstrate that OSW-1 inhibits ganglioside GD3 in melanoma cells by 
repressing gene expression of the enzyme, GD3 synthase (ST8SIA1 gene), which catalyzes 
the biosynthesis of ganglioside GD3 from its precursor GM3 by addition of a second sialic 
acid residue (163, 164). Consequently we observed a moderate decrease in ganglioside GD3, 
a more significant inhibition of its downstream product, GD2 and an accumulation of the 
precursor GM3 (figure 3.11). Importantly, this inhibition of ganglioside GD2 correlated with 
the cell death effect (represented by MMP) of OSW-1 in melanoma cells (figure 3.19). 
Nevertheless, it is unresolved if GD3S is a direct target for OSW-1 in melanoma. 
Interestingly, the OSW-1 structural analog, Triptolide, induced down regulation of human 
GD3 synthase (hST8SIA1) gene expression through NF-κB activation in melanoma cells 
(56). In addition, the transcription factor TWIST and GNE kinase are also known to 
positively regulate GD3S expression (165, 166). Therefore, it might be important to examine 
the effect of OSW-1 on signaling transduction proteins that are upstream of GD3 synthase. 
Another key protein that may potentially be a cellular interacting target of OSW-1 is the 
steroid regulatory element binding protein (SREBP), which acts as a master transcription 
factor regulating cholesterol and fatty acid biosynthesis (167). Prior structure-activity 
relationship studies demonstrated that the steroid nucleus in OSW-1’s structure was critical 
to its potent cytotoxic effect (66, 72). The SREBP protein, because of its ability to bind to 
sterol regulatory elements (168), may form a putative binding partner of OSW-1. Further, 
OSW-1 treatment inhibits expression of lipogenesis genes, FASN and HMGCR, which are 
downstream targets of SREBP. Cumulatively, these results point towards the possibility of 
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SREBP being a direct target of OSW-1 in melanoma cells. My future studies will be directed 
towards characterizing the molecular binding target(s) of OSW-1, with a strong focus on 
SREBP. Please refer to chapter 5(summary and future directions) for a detailed description of 
my experimental plans for this aspect of the OSW-1 future study.VDAC1 is a multifunctional 
channel protein involved in mitochondria dependent cell death, redox metabolism, and 
cancer cell signaling. It has been implicated in cell death induction by stimuli such as 
cisplatin, curcumin, myostatin, UV irradiation and oxidative stress through either homo-
oligomerization or interaction with Bcl-2 family proteins, adenine nucleotide translocase 
(ANT), regulation of Ca2+ and ATP flux, or ROS detoxification (169, 170). Our original 
results demonstrated that OSW-1 induced interaction between ganglioside GD3 and VDAC1 
in the mitochondrial membranes (figure 3.17, 3.18). Hence we characterized the effect of 
OSW-1 on VDAC1 expression and VDAC1 dependent cell death signaling in melanoma. 
Our data indicated that OSW-1 caused VDAC1 upregulation, increased cytosolic calcium 
and mitochondrial superoxide release in melanoma cells (figures 3.20, 3.23, 3.24). 
Interestingly, Triptolide, which inhibits GD3S, also activated VDAC1expression (figure 
3.22). Nevertheless, combination of OSW-1 with the VDAC inhibitor, DIDS, did not affect 
OSW-1 mediated ganglioside GD3/GD2 inhibition (figure 3.30), thus suggesting that GD3S 
might regulate VDAC1 expression but not vice versa. Significantly, combination of OSW-1 
with the immunosuppressant drug, cyclosporin A, not only upregulated VDAC1 expression 
but also led to elevated cell death (figure 3. 26 A, 3.25). Considering that combination 
therapy with cyclosporine has been known to improve clinical efficacy in advanced 
malignancies, we propose that this OSW-1+CsA treatment strategy may improve the 
therapeutic benefit of OSW-1 in melanoma and thus merits further investigation (171, 172). 
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Finally, knock out or knock down of VDAC1 ameliorated the cytotoxic effect of OSW-1 in 
melanoma (figure 3.28, 3.29), thus corroborating our findings that VDAC1 and mitochondria 
dependent cell death mechanisms are crucial to the antineoplastic activity of OSW-1.      
Increased expression of gangliosides GD3 and GM3 in melanoma cell lines and 
tissues, and a correlation between GD3 expression levels and the GD3 synthase enzymatic 
activity in cells has been reported (53, 54, 173). This is obvious in the comparison between 
melanoma cells and normal melanocytes wherein the melanocytes exhibit extremely low 
GD3 synthase activity and GD3 cell surface expression (16). Based on this information, we 
postulated that differential ganglioside expression profile may form a basis for the 
therapeutic selectivity of OSW-1 towards melanoma cells with limited toxicity to normal 
melanocytes (figure 3.9, 3.10). To test this hypothesis, we compared the basal ganglioside 
expression pattern between the OSW-1 resistant WM35DW and the parental WM35 cells 
(figure 3.32). Our results indicate WM35DW cells have a reduced GD3 and GD2 expression 
than the parental WM35 cells. A decreased free radical expression profile was also observed 
in the resistant WM35DW cells (figure 3.33). RPPA analysis revealed altered expression of 
multiple lipid metabolism proteins including FASN, YAP, FAK and caveolin-1 in WM35 vs. 
WM35DW cells (figure 3.35 A, B). Differential expression of mitochondrial signaling 
proteins such as VDAC1, cyclophilin and various interacting partners of VDAC1 such as 
Bcl-2 family members, and GSK3 was also observed (figure 3.35 A, C). Further 
investigation into the molecular mechanisms regulating GD3 synthase activity and the cell 
signaling regulating VDAC1-GD3 interaction may provide deeper insights into the 
therapeutic basis for the selective elimination of melanoma cells by OSW-1.  
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 In summary, our study delineates the mechanisms essential to the highly potent 
anticancer activity of OSW-1 in melanoma cells. Our results demonstrate that OSW-1 
induces autophagic cell death in melanoma by repressing GD3 synthase gene expression, 
leading to inhibition of gangliosides GD3, GD2 and accumulation of GM3. Ganglioside GD3 
then interacts with the mitochondrial VDAC1 leading to mitochondrial membrane potential 
collapse, aberrant calcium signaling and cell death. VDAC1 is a critical player in mediating 
OSW-1’s activity as its down regulation confers resistance to OSW-1. A significant 
characteristic of OSW-1 induced cytotoxicity is its therapeutic selectivity towards melanoma 
cells. Our investigation reveals that elevated ganglioside expression in melanoma may form 
the basis for the increased sensitivity of these cells towards OSW-1. To our knowledge, this 
is the first study to demonstrate the antitumor effect of OSW-1 on ganglioside expression and 
VDAC1 mediated mitochondrial signaling in melanoma. The role of OSW-1 as an inhibitor 
of GD3 synthase gene expression is crucial, since in melanoma ganglioside GD3 is a well 
characterized therapeutic target. Therefore, further research needs to be undertaken to shed 
light on the mechanisms regulating this GD3 synthase inhibition by OSW-1.   
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Chapter 4: PEITC effectively eliminates melanoma cells through redox mechanisms 
4.1: Introduction 
 PEITC is a highly active metabolite of cruciferous vegetables with potent 
chemopreventive and chemotherapeutic properties. It inhibits expression of pro-oncogenic 
proteins such as Bcl-2, Mcl1 and Bcl-xL, triggers cell cycle arrest, DNA and mitochondrial 
damage leading to caspase activation, cytochrome c release and apoptosis (95, 98).  
PEITC exhibits a unique mechanism of cell death – it induces excessive ROS 
accumulation in cancer cells leading to massive cytotoxicity (63, 64, 94). This ROS induced 
toxicity by PEITC is specific to tumor cells; normal melanocytes with a lower basal oxidative 
stress phenotype and reserve antioxidant capacity are resistant to PEITC and other pro-
oxidant compounds (63).  
In this dissertation, I investigated the mechanisms of cytotoxic action and therapeutic 
selectivity of PEITC in melanoma cells. I aimed to characterize the differences in redox 
status between the normal cells and cancer cells and use this as a mechanistic basis to 
specifically eliminate melanoma cells. My results demonstrate the PEITC depletes cellular 
glutathione in melanoma cells leading to ROS stress, loss of mitochondrial membrane 
potential and cell death through apoptosis. Further, a positive correlation between the basal 
cellular ROS expression levels and sensitivity to PEITC was observed. Accordingly, normal 
melanocytes which have a much lower intrinsic oxidative stress compared to melanoma cells 
are resistant to PEITC. The glutathione depletion mediated by PEITC is an early event which 
occurs much before cell death and is crucial to the cytotoxic effect of PEITC in melanoma. 
Due to this distinctive mechanism of cell death, PEITC is effective in attenuating drug 
resistance to clinically used melanoma agents. 
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4.2 Results 
4.2.1 Redox status of melanoma cells  
A characteristic feature of melanoma biology is the presence of aberrant 
melanosomes in melanoma cells that generate free radicals (174). Chronic oxidative stress 
potentiated by oncogenic Akt signaling or loss of tumor suppressors such as p53 and p16, in 
combination with exposure to ultraviolet radiations (UV), UVA and UVB, may lead to 
oncogenic transformation of dysplastic nevi and development of an intrinsic drug resistant 
phenotype in melanoma cells (44, 62, 175-177). On the other hand, excessive reactive 
oxygen species (ROS) accumulation in melanoma cells leads to massive toxicity and cell 
death, thus making it a unique therapeutic target. Hence, I hypothesized that melanoma cells 
are under elevated intrinsic oxidative stress and can be preferentially eliminated by 
pharmacological agents such as PEITC which modulate the cellular redox homeostasis.  
To investigate this hypothesis, we first characterized the basal redox status of 
melanoma cells. The intracellular free radical expression levels were determined across a 
panel of melanoma cells by flow cytometric analysis using the fluorescent reagents, CM-H2-
DCFDA, DAF-FM and dihydroethidium. 5-,6-Chloromethyl-2’7’-
Dichlorodihydrofluorescein Diacetate (CM-H2-DCFDA) is an indicator of hydroxyl radicals, 
peroxides and other ROS molecules in cells. DCFDA passively diffuses into the cells, where 
its acetate groups are cleaved by intracellular esterases and the compound is subsequently 
oxidized to yield the fluorescent 2’7’-Dichlorofluorescein (DCF), which can be detected by 
flow cytometry (178). 4-Amino-5-Methylamino-2', 7’-Difluorofluorescein (DAF-FM) 
detects nitric oxide (NO) in cells. The non-fluorescent DAF-FM reacts with intracellular NO 
and is converted into the fluorescent benzotriazole molecule which can be quantified (179).  
Dihydroethidium (Het) is a blue fluorescent dye which is oxidized by superoxides to form 
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oxiethidium, which then intercalates with nucleic acids to emit a bright red fluorescence that 
can be detected by flow cytometry or microscopy (180).  
Our results indicated that Hs294T (BRAF WT, metastatic) melanoma cells had the 
highest expression of basal ROS and nitric oxide (figure 4.1 A, B, D). Superoxide levels 
were elevated across the melanoma cells evaluated in this study. Overall, SK-MEL-2 (BRAF 
WT, NRAS Q617R, metastatic) cells contained relatively higher free radical expression 
among the melanoma cells tested (figure 4.1). The A375SM (BRAF V600E, NRAS WT, 
highly metastatic) cells had a moderately decreased free radical expression profile compared 
to the other melanoma cells (figure 4.1). Hence, SK-MEL-2 and A375SM cells were used as 
representative cell line models in the follow-up mechanistic studies.  
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Figure 4.1: 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Basal free radical expression profile in melanoma cells. 
(A), (B), (C) Melanoma cells were plated in 6-well plates for 24 h prior to the measurement 
of cellular reactive oxygen species, nitric oxide and superoxides using the fluorescent probes 
DCFDA, DAF-FM and Dihydroethidium by flow cytometry. (D) Mean count of the basal 
reactive oxygen species, nitric oxide and superoxide expression levels in melanoma cells.   
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4.2.2 The cytotoxic effect of PEITC in melanoma 
Earlier studies from our lab demonstrated that the natural product, PEITC was 
effective in inhibiting leukemia cells including fludarabine resistant chronic lymphocytic 
leukemia and Gleevec-resistant chronic myelogenous leukemia (63, 102). To investigate the 
effect of PEITC on melanoma cell viability, I performed an MTT assay across a panel of cell 
lines treated with varying concentrations of PEITC for 72 h. As illustrated in figure 4.2, 
PEITC was cytotoxic to melanoma cells with an average half-maximal inhibitory 
concentration (IC50) of 2.21 µM. Interestingly, WM46 cells which have the lowest levels of 
basal ROS expression amongst all the melanoma cells tested (figure 4.1D), also have the 
highest IC50 value (4.10 µM; figure 4.2B). 
Biochemical analysis by annexin V-FITC/propidium iodide staining indicated that 
PEITC induced apoptosis in melanoma cells in a time dependent fashion (figure 4.3A, B). 
PEITC induced cell death was detectable at 12 h and reached over 70% by 24 h in A375SM 
and SK-MEL-2 cells (figure 4.3A). The bar graphs in figure 4.3B represent the heterogeneity 
of melanoma cell response to PEITC. On average, a 24 h PEITC treatment caused 55.73% 
(DMSO vs. PEITC 24h, p-value < 0.0001) cell death in melanoma cells. Significantly, 
combination of PEITC with the pan caspase inhibitor, Z-VAD-FMK, partially rescued 
melanoma cells from the cytotoxic effect of PEITC (figure 4.3C). Caspases are a group of 
intracellular proteases that play a pivotal role during apoptosis by catalyzing the disassembly 
of cells into membrane-enclosed vesicles (apoptotic bodies), ultimately leading to death 
(181). Treatment of SK-MEL-2 cells with 5 µM PEITC induced 71.74% cell killing. 
However, co-treatment of cells with 20 µM Z-VAD-FMK and 5 µM PEITC reduced cell 
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death to 30.23% (figure 4.3C). These results delineate the role of caspase activation and 
apoptosis in mediating the inhibitory activity of PEITC.             
Figure 4.2:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Effect of PEITC on melanoma cell viability 
Melanoma cells were treated with log-scale serial diluted concentrations of PEITC for 72 h, 
and the cytotoxic effect was determined by performing the MTT assay. The cell viability 
curves were plotted. Each data point represents mean ± SEM for three independent 
measurements. (B) The 50% cell inhibitory concentrations (IC50) of PEITC for each cell line 
are indicated. 
Cell line IC50 Value 
 (µM) 
Mean ± SEM 
(µM) 
A375SM 2.42 ± 0.179  
 
 
 
 
2.206 ± 0.362 
WM35 1.52 ± 0.327 
SK-MEL-2 2.70 ± 0.418 
WM46 4.10 ± 0.618 
UCSD354L 2.18 ± 0.219 
HS294T 1.00 ± 0.140 
MEL624 2.67 ± 0.295 
MEWO 1.06 ± 0.241 
A 
B 
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 Figure 4.3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91.8% 84.4% 71% 23% 
94.2% 75.5% 60.7% 21.3% 
Pr
op
idi
u
m 
io
di
de 
Annexin V-FITC 
DMSO 6 h 12 h 24 h 
10 µM PEITC 
A375SM 
SK-MEL-2 
DMSO 20 µM Z-VAD-FMK 5 µM PEITC PEITC + Z-VAD-FMK
91.3% 93.4% 25.8% 63.7% 
A 
C 
* 
** 
* 
* 
* 
* 
* * 
* 
**** 
* 
** 
*** 
** 
**** 
*** 
** * 
* 
P=0.069 
P=0.128 P=0.173 
P=0.180 P=0.057 
P=0.088 
P=0.065 
P=0.198 P=0.242 P=0.201 
B
* 
 101 
 
 
Figure 4.3: PEITC induced cytotoxicity is through apoptosis in melanoma cells 
(A) SK-MEl-2 and A375SM cells were treated with 10 µM PEITC for the indicated time 
points and PEITC induced cell death induced was detected by annexin V-FITC/PI staining 
and flow cytometric analysis as described in materials and methods. (B) Percent cell viability 
of melanoma cells treated with 10 µM PEITC for the indicated time points. Bar graphs 
represent mean ± SEM of three independent measurements. (C) SK-MEL-2 cells incubated 
in 20 µM Z-VAD-FMK for 1 h were treated with 5 µM PEITC for 24 h and cell death was 
measured by flow cytometric analysis (annexin V-FITC/PI staining). **** denotes p < 
0.0001, *** denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05. 
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Mitochondrial dysfunction constitutes an important event in the induction of cell 
death. Opening of the mitochondrial transition pore leading to depolarization of membrane 
potential, release of apoptogenic proteins and uncoupling of oxidative phosphorylation have 
been linked to apoptosis stimulation by agents such as tert-Butylhydroperoxide, the calcium 
ionophore A23187, selenite, sulforaphane etc. (182-186). To test if PEITC caused 
mitochondrial membrane damage in melanoma, I treated the cells with 5 µM PEITC for 
varying time points and the effect on mitochondrial membrane integrity was assessed by flow 
cytometric analysis of cells labeled with Rhodamine 123, a lipophilic, cationic fluorescent 
dye that is readily taken up by active mitochondria. Depolarization of the mitochondrial 
membrane, therefore, decreases the mitochondrial rhodamine 123 signal, which can be 
quantified (187). My results indicate that PEITC potentiated a time-dependent mitochondrial 
membrane potential collapse in SK-MEL-2 and A375SM cells (figure 4.4). Mitochondrial 
membrane permeabilization was first observed at 16 h and by 24 h there was a massive (over 
90%) loss of membrane potential in PEITC treated cells as compared to the DMSO treated 
controls (DMSO vs. PEITC 24h, p-value < 0.0001). 
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Figure 4.4: 
 
 
 
 
 
 
 
 
 
Figure 4.4: PEITC induces mitochondrial membrane potential loss in melanoma cells. 
A375SM and SK-MEL-2 cells were treated with 5 µM PEITC for the indicated time points 
and the effect on mitochondrial membrane potential was evaluated by flow cytometric 
analysis of Rhodamine 123 labelled cells.  
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Figure 4.5: 
       
Figure 4.5: Correlation between cellular basal ROS levels and cell death induced by 
PEITC.  
Cellular intrinsic ROS expression levels were measured by performing the DCFDA assay. 
Cell death was detected by annexin V-FITC/PI assay in melanoma cells treated with 10 µM 
PEITC for 24 h. Linear regression analysis between these two parameters was performed 
using the mean ± SEM measurements of three independent experiments.  
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Figure 4.6: 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Effect of PEITC on JNK and p38 expression in melanoma. 
SK-MEL-2 cells were treated with 5 µM PEITC for the indicated time points and the effect 
on JNK and p38 kinase expression was assessed by western blotting.  
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Quantitative evaluation of the relationship between basal cellular ROS levels and 
PEITC induced cell death revealed a strong correlation between these two parameters (r = 
0.8068, p-value = 0.0155) (figure 4.5). ROS have been known to promote apoptotic signaling 
by mediating the activation of pro-apoptotic JNK and ASK1 kinases, leading to upregulation 
of TNFα, Fas-L and Bak, release of  cytochrome C, and mitochondrial translocation of Bax 
and Bad apoptotic proteins (188-191). Interestingly, western blot analysis indicated that 
PEITC stimulated a time-dependent increase in phosphorylated-JNK expression in SK-
MEL2 cells (figure 4.6). However, no significant change was observed in the expression of 
total JNK as well as total and phosphorylated p38 MAP kinase (figure 4.6). Collectively 
these results indicate that PEITC executes its anticancer effect through apoptosis and ROS 
mediated mechanisms in melanoma cells. Of significance is the observation that the basal 
ROS status of melanoma cells is proportional to its sensitivity to PEITC.  
4.2.3 PEITC exhibits minimal toxicity in normal melanocytes 
The promising cytotoxic activity of PEITC in melanoma cells led us to investigate the 
effect of this compound on normal melanocyte cell viability.  As shown in figure 4.7, normal 
melanocytes were significantly less sensitive to PEITC compared to melanoma cells. 
Annexin-FITC/PI analysis demonstrated that a 24 h PEITC treatment caused 60% cell death 
in melanoma cells (n = 9), while 94.73% of normal melanocytes were still viable at this time 
point (figure 4.7B). Interestingly, PEITC stimulated massive cytotoxicity in HS294T (figure 
4.7A) and SK-MEL-2 (figure 4.3A) melanoma cells, which have a relatively higher ROS 
capacity. Previous research findings have shown that PEITC mediated cell death is 
characterized by ROS production either though depletion of the glutathione antioxidant 
system or inhibition of oxidative phosphorylation in leukemia, ovarian and prostate cancers 
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(63, 64, 113). This led me to speculate that the anticancer effect of PEITC relied on 
disrupting on the cellular redox homeostasis leading to ROS accumulation and subsequent 
toxicity. As expected, incubation of SK-MEL-2 cells with 5 µM PEITC for 8 h resulted in 
substantial ROS accumulation, whereas only a slight increase in ROS levels was observed in 
normal melanocytes (figure 4.8). These results suggest that distinct redox regulatory 
mechanisms exist between melanoma cells and normal melanocytes and these may form the 
basis for their differential response to PEITC.  
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Figure 4.7: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Preferential killing of melanoma cells by PEITC 
(A) Cell death induced by 10 µM PEITC in melanoma cells and normal melanocytes was 
determined by flow cytometric analysis of annexin V-FITC/PI stained cells. Representative 
dot blots are shown here. (B) Bar graphs illustrate the quantitative comparison of PEITC 
triggered cell death (normalized to DMSO control) in melanoma (n = 9) and normal 
melanocyte cells at 24 h treatment. Mean ± SEM of cell death measurements from three 
independent experiments of each melanoma cell line and normal melanocytes is denoted 
here.  ** denotes p < 0.01. 
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Figure 4.8: 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Induction of ROS accumulation in melanoma cells and normal melanocytes 
by PEITC.  
SK-MEL-2 cells and normal melanocytes were treated with 5 µM PEITC for 8 h and ROS 
levels were detected by flow cytometric analysis of cells labelled with 1 µM DCFDA. 
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Figure 4.9: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Comparison of ROS expression between melanoma cells and normal 
melanocytes. 
(A) and (C) Flow cytometric analysis to detect ROS (DCFDA) and specifically 
superoxides (Dihydroethidium) was performed in SK-MEL-2 and normal melanocytes 
(NHEM) stained with 1 µM DCFDA and Dihydroethidium. (B) and (D) Bar graphs 
represent the mean ± SEM of ROS and superoxide measurements from three independent 
experiments of each melanoma cell line (n = 8) and normal melanocytes.  ** denotes p < 
0.01 and * denotes p< 0.05. 
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 The preferential ROS accumulation in melanoma cells treated with PEITC suggested 
that these cells were under increased intrinsic oxidative stress thus making them more 
vulnerable to further free radical elevation and redox disturbance by PEITC. To evaluate this 
observation, I compared the basal ROS and specifically superoxide expression levels 
between melanoma cells and normal melanocytes. As illustrated in figure 4.9 A and B, 
melanoma cells exhibit increased ROS expression compared to normal melanocytes (P-value 
< 0.05). SK-MEL-2 cells had a 2.3 fold increased intrinsic ROS expression compared to 
normal melanocytes (figure 4.9A). Importantly, the intrinsic superoxide levels were 3-fold 
higher (p-value < 0.01) in melanoma cells than the normal melanocytes (figure 4.9D). A 
representative histogram indicating the differential superoxide expression in melanoma cells 
is shown in figure 4.9C. Based on these results, I concluded that the higher intrinsic oxidative 
stress observed in melanoma cells was important in modulating their sensitivity to PEITC. 
4.2.4 The ROS mediated mechanisms of cell death by PEITC  
 Treatment of SK-MEL-2 and A375SM cells with 5 µM PEITC produced a time 
dependent increase in cellular ROS levels (figure 4.10B). A 6 h PEITC incubation of SK-
MEL-2 cells increased cellular ROS levels by 3.2-fold (figure 4.10A). In contrast, PEITC (10 
µM, 8 h) did not induce any significant ROS change in normal melanocytes (figure 4.8), 
suggesting that this ROS elevation rendered the melanoma cells susceptible to PEITC’s 
cytotoxic activity.  Interestingly, flow cytometric analysis of melanoma cells stained with 
Dihydroethidium indicated that PEITC treatment did not generate any significant change in 
the cellular superoxides (O2¯ ) (figure 4.10D), although the intrinsic superoxide expression 
was significantly increased in melanoma cells compared to normal melanocytes (figure 4.9 
C, D). PEITC stimulated a time dependent increase in nitric oxide levels (figure 4.10C).  
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Figure 4.10: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Effective killing of melanoma cells through ROS induced damage 
(A), (C) and (D): SK-MEL-2 cells were treated with 5µM PEITC for the indicated time 
points and alterations in ROS, nitric oxide and superoxide expression in cells was assessed 
by DCFDA, DAF-FM and dihydroethidium staining. (B) A375SM and SK-MEL-2 cells were 
treated with 10µM PEITC for a varying time course and DCFDA assay was performed. *** 
denotes p < 0.001, ** denotes p < 0.01 and * denotes p< 0.05. 
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 Cumulatively, these results suggest that PEITC induced ROS may include other 
molecules such as hydrogen peroxide, hydroxyl radical and nitric oxide but not superoxides. 
This data corroborates with previous findings from our lab in oncogenic Ras transformed 
ovarian epithelial cells (T72 Ras) where PEITC induced ROS and NO generation, without 
any significant changes in O2¯  (113).  Further, the relationship between ROS accretion and 
PEITC mediated toxicity was quantitatively evaluated by plotting PEITC induced cell death 
as a function of ROS increase (figure 4.11). A positive correlation (r = 0.7357, p-value < 
0.05) between these two factors was observed. 
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Figure 4.11: 
    
 
 
                 
  
 
Figure 4.11: Correlation between cell death and PEITC induced ROS stress 
Cell death was detected by annexin V-FITC/PI assay in melanoma cells treated with 10 µM 
PEITC for 24 h. ROS expression levels in PEITC treated melanoma cells were measured by 
DCFDA assay. Cell death was plotted as a function of ROS fold change and linear regression 
analysis was performed.  
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Since PEITC triggered cell death was characterized by ROS accumulation in cells, I 
next investigated the potential cause for this ROS stimulation by PEITC. Glutathione is a 
major antioxidant which has been shown to promote metastatic melanoma cell survival in the 
hepatic microvasculature by protecting the cells against oxidative stress induced damage 
(192). Importantly, glutathione depletion either by pharmacological intervention using L-
Buthionine (S, R)-Sulphoximine (BSO) or by dietary modulation using an L-glutamine 
enriched diet reduced melanoma tumor growth and sensitized cells to combination therapy 
(192, 193). Further, studies by Trachootham et al., and Lam et al., indicated that PEITC 
scavenges glutathione in leukemia and breast cancer cells leading to massive cytotoxicity 
(93, 113). I postulated that the high ROS capacity in malignant melanoma cells would make 
them dependent upon the glutathione antioxidant system to maintain redox balance in cells, 
and therefore depletion of glutathione by PEITC would disrupt the redox homeostasis 
resulting in excessive ROS accumulation, beyond the cell’s tolerance threshold, and 
subsequent cell death. To examine this hypothesis, I treated SK-MEL-2 and A375SM cells 
with 5 µM PEITC for 3 and 6 h and detected the cellular glutathione levels (figure 4.12). 
PEITC induced inhibition of glutathione was detected at 3 h and by 6 h about 60% of cellular 
glutathione was depleted. It is important to note that PEITC treatment exhibits limited 
cytotoxicity at these time durations (figure 4.3B), suggesting that this glutathione depletion 
may be a primary event that potentiates ROS accumulation and consequent cell death. To 
verify this possibility, I treated SK-MEL-2 and A375SM cells pre-incubated in the 
glutathione precursor, N-Acetyl Cysteine (NAC) with PEITC (figure 4.13). As shown in 
figure 4.13 A and B, NAC reverses the ROS elevation caused by PEITC. More importantly, 
combination of NAC with PEITC completely abrogates the cytotoxic effect of PEITC in SK-
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MEL-2 cells (figure 4.13C). Hence glutathione depletion is an important mechanism in 
PEITC induced ROS increase and cell death.          
 
 
 
Figure 4.12:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: PEITC causes depletion of cellular glutathione. 
A375SM and SK-MEL-2 cells were treated with 5 µM PEITC for the indicated time points 
and cellular glutathione levels were detected by spectrophotometric analysis as described in 
materials and methods. ** denotes a statistical significance of p < 0.01 between the DMSO 
control and PEITC treated samples in each of the respective cell lines . 
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Figure 4.13: 
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Figure 4.13: N-Acetyl Cysteine (NAC) reverses the inhibitory effect of PEITC 
(A) SK-MEL-2 cells incubated in 1 mM NAC for 2 h were treated with 5 µM PEITC for 6 h 
and ROS were detected by the DCFDA assay.  (B) Bar graphs denote the mean ± SEM of 
three independent measurements of ROS in A375SM and SK-MEL-2 cells treated with 
PEITC ± NAC. (C) Annexin V-FITC/PI assay was performed to detect the effect on cell 
death in SK-MEL-2 cells treated with PEITC ± NAC for 24 h. **** denotes p < 0.0001 and 
*** denotes p < 0.001. 
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4.2.5 Combination of Temozolomide / BCNU with PEITC attenuates drug resistance to 
these agents in melanoma 
Malignant melanomas are characterized by significant drug resistance to currently 
used chemotherapeutic agents such as Temozolomide (TMZ) and 1,3-bis-(2-chloroethyl)-1-
nitrosourea (BCNU).   Interestingly, BCNU has been shown to inhibit glutathione reductase 
activity in erythrocytes from patients as well as in mouse liver, lung and heart tissues (194, 
195). Further, Kohsaka et al. demonstrated that combination of TMZ with the glutathione 
synthesis inhibitor, BSO, potentiated the toxic effect of Temozolomide in TMZ resistant 
glioblastoma cells (196). Based on this information, I postulated that combination of PEITC 
with either BCNU or TMZ would cause incremental oxidative stress due to an enhanced 
depletion of cellular glutathione. This would lead to significant toxicity in melanoma cells 
and would be of therapeutic benefit. Towards this end, I first performed annexin V-FITC/PI 
assay to examine the effect of PEITC ± TMZ/BCNU combination on cell death in melanoma 
cells (figure 4.14). The results indicate that supplementation of PEITC with either BCNU or 
TMZ promoted significantly higher inhibitory effect than that of any (PEITC/TMZ/BCNU) 
single agent treatment. The cytotoxic effect of this drug combination was evaluated by 
performing the colony formation assay. As illustrated in figure 4.15, PEITC, BCNU or TMZ 
as a single agent moderately inhibited colony formation (figure 4.15 A, C). However, 
combination of TMZ/BCNU with PEITC caused a striking decrease in the number of 
colonies formed. For instance, PEITC+BCNU treatment potentiated 3.5-fold decrease in the 
number of colonies as compared to PEITC single agent treatment (figure 4.15B).   
Furthermore, combination index (CI) analysis using the Chou-Talalay algorithm was 
performed to characterize the type of drug interaction (figure 4.16). SK-MEL-2 cells were 
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incubated with varying combination regimens of PEITC (5 µM, 10 µM and 20 µM; last 24 h) 
and BCNU (50 µM, 100 µM and 200 µM; 48 h) or TMZ (0.3 mM, 0.6 mM and 1 mM; 48 h). 
As described in figure 14.6B, the combination of PEITC with TMZ was synergistic (CI<1.0). 
Similarly, BCNU and PEITC combination index analysis mostly produced synergistic and 
additive (CI=1) end points (figure 4.16D).  
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Figure 4.14: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Effect of PEITC ± TMZ/BCNU treatment on melanoma cell viability 
SK-MEL-2 and A375SM cells were incubated in varying concentrations of BCNU and TMZ 
for 48 h. During the last 24 h of treatment 5 µM PEITC was added and the effect of the drug 
combination on cell death was determined by annexin V-FITC/propidium iodide staining. 
Bar graphs represent the percentage of viable cells in each drug treatment sample as a 
function of the DMSO treated control cell viability.  **** denotes p < 0.0001, *** denotes p 
< 0.001, ** denotes p < 0.01 and * denotes p< 0.05. 
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Figure 4.15: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Combination of Temozolomide / BCNU with PEITC inhibits colony 
formation in melanoma cells 
(A) and (C) A375P cells were treated with the indicated concentrations of PEITC and 
BCNU/TMZ for 2 weeks and the effect of the drug combination on colony formation was 
determined by Giemsa staining. (B) and (D) The colonies formed were counted manually and 
have been represented as bar graphs. *** denotes p < 0.001, ** denotes p < 0.01 and * 
denotes p< 0.05. 
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Figure 4.16: Combination index analysis of PEITC ± TMZ/BCNU treatment 
(A) and (C) Representative dot blots indicating cell death induced  by TMZ ± PEITC and  
BCNU ± PEITC 48 h treatment in SK-MEL-2 cells. PEITC was added during the last 24 h of 
treatment. (B) and (D) SK-MEL-2 cells were treated with the indicated concentrations of 
PEITC ± TMZ/BCNU for 48 h, and combination index (CI) analysis was performed using 
Compusyn software.  The following quantitative definitions, based on the Chou-Talalay 
theorem, were employed to define combination effect: CI < 1 represents synergism, CI = 1 
represents an additive effect, and CI > 1 represents antagonism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 125 
 
Figure 4.17: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Redox mechanisms mediate the combinatorial cell death effect of TMZ/ 
BCNU ± PEITC treatment in melanoma. 
(A) Melanoma cells were treated with 0.5 mM TMZ for 24 h. 5 µM PEITC was added during 
the last 6 h of treatment. ROS, nitric oxide and mitochondrial superoxides were measured by 
DCFDA, DAF-FM and mitosox red staining and flow cytometric analysis. (B) 5 µM PEITC 
was added during the last 3h of a 24 h 100 µM BCNU or 0.5mM TMZ treatment. Bar graphs 
represent mean ± SEM of cellular glutathione measurements for the indicated drug 
concentrations in three independent experiments. * denotes p< 0.05.   
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To delineate the mechanisms that are pivotal to this increased cytotoxicity of 
PEITC+TMZ/BCNU drug combination in melanoma cells, we analyzed for changes in redox 
expression in cells treated with PEITC ± TMZ/BCNU. Co-treatment of PEITC (5 µM, 6 h) 
with TMZ (0.5 mM, 24 h) led to increased ROS and nitric oxide generation as compared to 
the effect of PEITC as a single agent (figure 4.17A, B). Also, Temozolomide, by itself, did 
not induce any significant changes in ROS. Further, this combination (PEITC+TMZ) also 
stimulated a slightly increased generation of mitochondrial superoxides as detected by the 
mitosox red indicator (figure 4.17C). Importantly, this ROS increase was preceded by 
glutathione depletion in SK-MEL-2 cells. Addition of 5 µM PEITC to melanoma cells pre-
incubated in BCNU or TMZ led to inhibited cellular glutathione. The glutathione depletion 
was higher in combinatorial treatment of PEITC+BCNU/TMZ as compared to a single agent. 
Thus, glutathione depletion forms a primary event in attenuating drug resistance to TMZ or 
BCNU in melanoma using the redox modulating agent, PEITC. 
 In conclusion, the natural product PEITC exhibits significant anticancer activity in 
melanoma. Its inhibitory effects in melanoma are mediated by ROS accumulation and 
disabling of the glutathione antioxidant system.  
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4.3 Discussion 
 Reactive oxygen species have been long known to promote melanoma development, 
metabolism and metastasis (38). However, the utility of ROS as a therapeutic target is yet to 
be characterized. Earlier studies in our lab revealed that pharmacologically induced ROS 
accumulation effectively eliminated cancer cells (61, 113). In this study, I demonstrate that 
the redox modulatory agent, PEITC selectively kills melanoma cells based on their 
differential intrinsic oxidative stress status as compared to normal melanocytes. Melanoma 
cells are under an elevated ROS stress and therefore, are dependent upon antioxidants to 
maintain redox balance. This makes them vulnerable to therapeutic agents that impair the 
cellular antioxidant system, leading to ROS accumulation and massive cytotoxicity. Normal 
melanocytes, on the other hand, are less susceptible to this strategy since they have a lower 
basal ROS expression and so any additional oxidative stress induced by pharmacological 
agents is still within the cells’ tolerance threshold. This biochemical difference between 
normal and cancer cells may be used to selectively eliminate melanomas. 
 The key conclusions from this study are: (a) PEITC is highly cytotoxic to melanoma 
cells with limited toxicity in normal melanocytes (figure 4.7). (b) Melanoma cells are under 
higher intrinsic oxidative stress compared to normal melanocytes (figure 4.9). Basal ROS 
expression levels of melanoma cells positively correlate with their sensitivity to PEITC 
(figure 4.5). (c) The elevated oxidative stress renders melanomas sensitive to PEITC which 
depletes the antioxidant glutathione, leading to severe ROS accumulation, mitochondrial 
membrane damage, activation of JNK kinase and rapid apoptotic cell death (figure 4.3, 4.4, 
4.6, 4.10, 4.12). In contrast, PEITC causes modest ROS increase in normal melanocytes, 
which is not significant enough to promote cell death (figure 4.8). Consequently, these cells 
 128 
 
are resistant to PEITC. (d) Inhibition of cellular glutathione by PEITC is a critical event since 
the glutathione precursor, NAC, reverses ROS accumulation as well as PEITC mediated cell 
death (figure 4.13). Furthermore, glutathione depletion can be detected much earlier than cell 
death suggesting that it is a primary event that instigates ROS elevation and PEITC induced 
toxicity in melanoma (figure 4.12). (e) Combination of PEITC with BCNU/TMZ ameliorates 
drug resistance to these agents in melanoma (figure 4.14, 4.16). Higher glutathione depletion, 
ROS accumulation and consequent cell death is observed in the samples treated with 
PEITC+BCNU/TMZ as compared to single agent treated samples (figure 4.17).       
 Trachootham et al. and Xu et al. demonstrated that PEITC disabled glutathione in 
leukemia cells by two mechanisms: conjugating with glutathione, thus promoting its export 
from the cells and inhibiting Glutathione Peroxidase (GPX) activity (100, 113). Interestingly, 
incubation of cells with 5 – 10 µM PEITC caused inhibition of glutathione in the mM range 
(113). A possible explanation for this stochiometric discrepancy may be that PEITC is 
concentrated at higher concentrations in cells. Indeed, incubation of the oncogenic T72Ras 
cells with 5 - 10 µM PEITC for 2 h led to intracellular concentrations of 0.25 – 0.59 mM. 
Subsequent biochemical analysis indicated that 0.5 mM PEITC suppressed GPX activity by 
over 90% in a cell-free enzyme assay. These data suggest that PEITC at µM concentrations, 
used in cell culture assays, may deplete the cellular glutathione pool and GPX enzyme 
activity significantly leading to ROS accumulation and cytotoxicity. PEITC mediated 
inhibition of oxidative phosphorylation and mitochondrial damage leading to ROS generation 
in leukemia and prostate cancer has also been reported (64, 94).  Furthermore, PEITC 
potentiated activation of JNK kinase in DU145 prostate cancer cells (197). Interestingly, this 
PEITC-induced apoptosis was attenuated by pharmacological inhibition of JNKs with 
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SP600125 suggesting that JNK activation was critical to PEITC’s activity in these cells 
(197). Stress induced activation of ERK1/2 was also observed. JNK proteins play a crucial 
role in regulating cytochrome C release and apoptosis induction following UV irradiation in 
MEF cells (198). JNK kinases have also been reported to activate apoptotic signaling by 
modulating the expression of pro-apoptotic and anti-apoptotic mitochondrial proteins (188, 
199, 200). PEITC causes a time dependent increased JNK phosphorylation in melanoma cells 
(figure 4.6). Considering that PEITC triggers apoptosis through mitochondrial membrane 
permeabilization and caspase activation (figure 4.3, 4.4), it is plausible that JNK proteins 
may be instrumental in mediating this cell death process. Further studies, using either 
inhibitors or siRNAs to downregulate JNK expression need to be undertaken to delineate the 
role of JNK in effecting PEITC’s cytotoxic activity in melanoma cells.  
 PEITC potentiated ROS accumulation in cells was detected by DCFDA and DAF-FM 
fluorescent probes but not by HEt suggesting that the free radicals activated by PEITC were 
mostly peroxides, hydroxyl radicals and nitric oxide but not superoxides (figure 4.10). 
Nevertheless, the basal superoxide expression in melanoma cells is significantly higher than 
normal melanocytes (figure 4.9C, D). This may be because of the rapid conversion of 
superoxides to hydrogen peroxide, peroxynitrites etc (201, 202).  
A recent study by Vazquez et al. (2013), demonstrated that the transcriptional co-
activator, PGC1α, promoted increased mitochondrial energy metabolism and ROS 
detoxification capacities in melanoma (203). Consequently, depletion of PGC1α in these 
cells sensitized them to ROS-inducing drugs such as PEITC and Piperlongumine (203). 
These results suggest that redox modulation therapies might be especially useful for the 
subset of melanomas which are PGC1α negative. Further, combining PGC1α inhibition with 
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ROS accretion (using PEITC or other ROS inducing agents) might be another strategy to 
increase drug sensitivity in PGC1α positive tumors. The mutant BRAF inhibitor, 
Vemurafenib promoted mitochondrial respiration and elevated ROS stress in BRAF V600E 
melanoma cells irrespective of their PGC1α status (204). Further, vemurafenib-resistant cells, 
generated by treating the parental A375, SKMEL28 and WM9 melanoma cells with 
increasing concentrations of vemurafenib, exhibited high mitochondrial activity and intrinsic 
oxidative stress compared to the parental cells (204). Importantly, the vemurafenib-resistant 
cells were more sensitive to pro-oxidative drugs such as Elesclomal and PEITC than the 
parental cells (204). Thus redox mediated cell death strategies find increasing utility in 
melanoma chemotherapy either as a single agent or in combination with currently used 
clinical melanoma drugs including vemurafenib.  
Recent studies reported that activation of oncogenes such as K-Ras and Akt in an 
inducible system led to an elevated intrinsic oxidative stress phenotype in cells (112, 205). 
Hence, cancer cells with these specific oncogene activations may be especially susceptible to 
ROS inducing agents. Nogueira et al., through in vitro and in vivo studies demonstrated that 
using PEITC (as a single agent or in combination with Rapamycin) in cancer cells with Akt 
activation may constitute a strategy to selectively inhibit these cells (205). This therapeutic 
scheme may be of significant utility in melanomas where 20% tumors exhibit PTEN loss 
leading to increased basal Akt activation (39).  
My results indicate that combination of PEITC with either BCNU or TMZ had a 
synergistic cell death effect (figure 4.16). The cytotoxicity of this drug combination was 
mediated by redox mechanisms wherein PEITC + TMZ treatment led to significantly higher 
glutathione depletion and ROS accumulation compared to that of a single agent treatment of 
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either PEITC or TMZ (figure 4.17). Glutathione efflux pumps (GS-X) play a major role in 
resistance to various chemotherapeutic inhibitors such as cisplatin, temozolomide, 
carmustine and other  alkylating agents, daunorubicin and natural products (206, 207). The 
drug resistance mediated by GS-X pumps directly correlates with the cellular glutathione or 
glutathione S- transferase (GST) levels and involves two mechanisms (a) formation of GSH-
S drug conjugate (b) exclusion of this GSH-S drug conjugate from the cell by the GS-X 
export carrier pump (208, 209). Incidentally, the glutathione synthesis inhibitor, BSO has 
been reported to partially reverse this GS-X pump induced drug resistance to alkylating 
agents in lung tumor cell lines (210). Previous reports have indicated that PEITC conjugates 
with glutathione causing its export from the cell (100). Hence, I propose that PEITC 
mediated export of glutathione by GS-X pumps would inhibit the exclusion of BCNU and 
TMZ from the cells. This would sensitize the cells to the DNA alkylating effects of 
Temozolomide/BCNU, trigger ROS elevation and subsequently cause cell death. Further 
investigation needs to be undertaken to shed light on the mechanisms that direct the 
synergistic combinatorial effect of PEITC+TMZ/BCNU in melanoma. These studies may 
constitute the future perspectives of this project. 
 In conclusion, my research on the anticancer effects of PEITC in melanoma cells 
presents a novel strategy to selectively kill melanoma cells based on the differential redox 
biology between normal melanocytes and melanoma cells. PEITC scavenges glutathione 
antioxidant system leading to ROS accumulation and cytotoxicity in melanomas. This unique 
mechanism of action of PEITC and other glutathione inhibitors such as BSO can be used to 
combat resistance to other chemotherapeutic agents such as Temozolomide, BCNU and 
Vemurafenib.  
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Chapter 5: Summary and future directions 
5.1 Summary  
 My PhD dissertation outlines two novel therapeutic strategies to effectively eliminate 
melanoma cells with limited toxicity to normal melanocytes.  
The saponin molecule, OSW-1 is highly cytotoxic to melanoma cells with half-
maximal inhibitory concentrations in the sub-nanomolar range. It induces autophagic cell 
death in melanoma cells by repressing the gene expression of GD3 synthase enzyme, leading 
to inhibition of gangliosides GD3, GD2 and accumulation of GM3. Ganglioside GD3 is 
overexpressed in melanoma cells and is a well characterized therapeutic target. OSW-1 also 
promotes co-localization of ganglioside GD3 with the mitochondrial voltage dependent anion 
channel 1 (VDAC1) protein. This causes VDAC1 upregulation, mitochondrial membrane 
permeabilization, superoxide release and loss of calcium homeostasis leading to cell death. 
The elevated GD3 and GD2 expression in melanoma cells may be the basis of therapeutic 
selectivity of OSW-1 against melanoma cells since the normal melanocytes as well as the 
OSW-1 resistant, WM35 DW cells exhibit a decreased basal GD3 and GD2 expression. 
Further studies need to be undertaken to identify the direct cellular binding target of OSW-1. 
Studies also need to focus on delineating the mechanisms of selectivity of OSW-1. 
The natural product PEITC relies on the redox differences between normal and cancer 
cells to selectively eliminate cancer cells. In my study, I first characterized the basal ROS 
and RNOS expression status of melanoma cells and normal melanocytes. I observed that the 
sensitivity of melanoma cells to PEITC correlated with the basal ROS expression status of 
the cells. Normal melanocytes with reduced intrinsic oxidative stress were resistant to 
PEITC. PEITC induced ROS accumulation and glutathione depletion in melanoma cells. 
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Glutathione depletion occurred much before cell death. Supplementing the cells with the 
glutathione precursor, NAC, reversed the ROS accumulation and apoptosis mediated by 
PEITC. This indicates that the glutathione depletion is an important mechanism to PEITC 
induced cytotoxicity. Further, drug combination of PEITC with TMZ or BCNU ameliorates 
the chemoresistance to these agents. Future studies will focus on investigating oxidative 
stress based strategies to combat drug resistance in melanoma. 
5.2 Future directions 
5.2.1 Mechanisms of selectivity of OSW-1 and PEITC against malignant melanoma cells  
Mechanisms of selectivity of OSW-1 towards melanoma cells: 
 An important feature of OSW-1 mediated cell death was its selectivity against 
melanoma cells with minimal toxicity to normal melanocytes. I generated OSW-1 resistant 
WM35 (WM35 DW) cells (figure 3.31) to characterize the mechanisms underlying this 
therapeutic selectivity of OSW-1. My results indicate that WM35DW cells have a reduced 
basal ganglioside GD3 and GD2 expression profile compared to the parent WM35 cells 
(figure 3.32).  This ganglioside expression pattern is similar to normal melanocytes which 
express only trace amounts of the pro-oncogenic ganglioside GD3 but prominent levels of 
the tumor suppressive ganglioside GM3 (16). OSW-1 inhibits GD3 by repressing gene 
expression of the enzyme GD3 synthase. Previous reports demonstrated an elevated 
expression of GD3 Synthase (GD3S) in melanoma compared to other cancers (173). Further, 
the initial NCI-60 cell line panel in vitro screening identified that melanoma cells (exhibit 
ganglioside GD3 overexpression) were more sensitive to OSW-1 than the other cell lines 
tested (67). Hence, I speculate that the differential ganglioside GD3 expression in normal 
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melanocytes compared to melanoma cells may form the basis for the selectivity of OSW-1 
against malignant melanoma cells. 
 In order to test this possibility, I would perform ganglioside GD3 overexpression 
experiments in normal melanocytes. I hypothesize that if GD3 mediated signaling is critical 
to executing the cytotoxic activity of OSW-1, then overexpressing GD3 in normal 
melanocytes by transfecting them with the GD3S gene would sensitize these cells to OSW-1. 
For this purpose, GD3 deficient SK-Mel-28 cells (referred as N1) as well as the GD3 
synthase overexpressing G5 and G11 cell clones that were established from N1 cells would 
serve as valuable cell models  (17, 211). If the GD3 expression status of the cell governs its 
sensitivity to OSW-1, then the N1 cells would be resistant to OSW-1 whereas the G5 and 
G11 SK-MEL-28 cells would exhibit increased sensitivity to OSW-1. I hope to initiate 
collaborations to acquire these cells and test them for the cytotoxic effect of OSW-1.  
 VDAC1 was a critical effector molecule in mediating the cell death effect of OSW-1. 
RPPA results showed that the OSW-1 resistant WM35 DW cells exhibited a lower basal 
expression of VDAC 1 and VDAC1 interacting proteins such as Bcl-2 and GSK-3 (figure 
3.35 A, C).  Further the VDAC1 knock out MEF cells (MEF VDAC1-/-) and siVDAC1 
transfected A375SM melanoma cells were resistant to OSW-1 (figure 3.28, 3.29). Hence, I 
think it is important to compare the basal VDAC1 expression levels across melanoma cell 
lines and the normal melanocytes and investigate if there is a correlation between VDAC1 
expression status and sensitivity to OSW-1.  It would be worthwhile to perform VDAC1 
transfection experiments in normal melanocytes to examine if induced expression of VDAC1 
would sensitize these cells to OSW-1. 
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 Finally OSW-1 mediated cell death in melanoma cells is through autophagy. 
Inhibition of autophagy by using pharmacological inhibitors or down regulating the 
expression of autophagy genes abrogates OSW-1 induced cell death (figure 3.6). Hence, I 
would investigate normal melanocytes and melanoma cells to ascertain if differences in 
intrinsic autophagy flux (as indicated by expression of p62, Beclin-1, Atg5, Atg 8) and 
mitochondrial mass between the cells contributes to their sensitivity to OSW-1. 
Mechanisms of melanoma cell selectivity of PEITC: 
PEITC inhibited prostate and leukemia cancer growth by disrupting mitochondrial 
oxidative phosphorylation (OXPHOS) leading to ATP depletion and ROS production (64, 
94). Further, ROS generation in was an early, upstream event that contributed to DNA 
fragmentation, collapse of mitochondrial membrane potential, cytochrome c release and 
apoptosis. Interestingly, this ROS production and other downstream events such as caspase 
activation and mitochondrial membrane damage were not observed in the OXPHOS deficient 
Rho-0 prostate cancer cells, indicating that oxidative stress were a crucial mechanism 
regulating the selectivity circuitry of PEITC (64). Similar results were observed in my study 
wherein ROS generation was observed much before cell death and normal melanocytes were 
resistant to free radical induction by PEITC. This ROS accumulation in melanoma cells was 
partly due to glutathione depletion. My next step would be to investigate the molecular 
mechanisms that promote ROS elevation in melanoma cells. Towards this end, my focus will 
be two-fold: investigate effect of PEITC on (a) mechanisms regulating glutathione 
biosynthesis and metabolism (b) mitochondrial respiration and the respiratory complex 
activity.       
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(a) Glutathione synthesis is a 2-step process:  γ-glutamyl cysteinyl synthetase (GCS) enzyme 
first catalyzes the generation of γ-glutamyl cysteine from cysteine and glutamate. Second, the 
glutathione synthetase enzyme combines γ-glutamyl cysteine and glycine to produce 
glutathione (GSH) (212). The availability of cysteine is the rate limiting step in this process 
(212, 213). The balance between reduced (GSH) and oxidized (GSSG) forms of glutathione 
in the cell is maintained by the enzymes glutathione peroxidase (GPX) and glutathione 
reductase (GR). Previous research from our lab indicated that PEITC inhibited glutathione 
peroxidase activity thus potentiating hydrogen peroxide accumulation in cells (113). First I 
would perform enzyme activity assays to determine if PEITC treatment abrogates the activity 
of GPX, GR, GCS and glutathione synthetase enzymes. The fact that supplementation of 
NAC reverses the cell death effect of PEITC (figure 4.13C) suggests that PEITC may not be 
inhibiting the activity of enzymes that catalyze glutathione biosynthesis (i.e. GCS and 
glutathione synthetase). After having identified the putative target enzyme modulated by 
PEITC, I would then examine the effect of PEITC on this target enzyme expression and 
activity in melanoma cells vs. normal melanocytes.     
(b) To examine the effect of PEITC on oxidative phosphorylation, I would employ the 
Seahorse Bioscience XF24 extracellular flux analyzer to compare oxygen consumption rate, 
and reserve respiration capacity in normal melanocytes and melanoma cells (both basal levels 
and PEITC induced changes). I would then use metabolic inhibitors such as oligomycin, 2-
Deoxy glucose, rotenone and carbonyl cyanide p-trifluoromethoxyphenyl hydrazone (FCCP) 
to determine the effect of PEITC on each of the mitochondrial respiratory complex activity. 
Simultaneously, I would perform western blots to test the effect of PEITC on mitochondrial 
respiratory complex (es) expression in both normal melanocytes and melanoma cells.   
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I believe that this two-fold approach to characterizing the mechanisms that regulate 
PEITC induced ROS accumulation in melanoma cells vs. normal melanocytes will provide 
insights into the selectivity of PEITC towards melanoma cells. 
5.2.2 Characterization of the direct molecular target for OSW-1: SREBP and GD3S 
regulatory signaling pathways 
 My PhD dissertation research demonstrates that OSW-1 represses the gene expression 
of GD3 synthase enzyme in melanoma cells. However, it remains unclear if GD3 Synthase is 
the direct target of OSW-1. The fact that OSW-1 inhibits GD3S gene expression points 
towards the possibility that OSW-1 may potentially interact/bind with a protein (such as a 
transcription factor) that is upstream of GD3 synthase signaling pathway and regulates its 
expression. Recent studies demonstrated that GD3 expression in melanoma cells correlated 
with activation of the steroid regulatory element binding protein (SREBP) leading to 
increased expression of HMGCR and elevated cholesterol biosynthesis (10). Burgett et al. 
(2011), through affinity chromatography and quantitative mass spectrometry approaches in 
HeLa-S3 cell lysate treated with the OSW-1 affinity reagent (prepared by covalently linking 
OSW-1 analogue to sepharose) identified the oxysterol binding protein (OSBP) as a cellular 
binding target of OSW-1 (69). However, the authors in this study did not explore the 
functional significance (such as effect on downstream proteins, signaling pathways etc.) of 
this interaction between OSW-1 and OSBP; nor did they prove that this interaction was 
imperative to mediating the cytotoxic effect of OSW-1. More importantly, shRNA mediated 
knockdown of OSBP expression did not exhibit a cytotoxicity profile similar to OSW-1 
treatment of cells, suggesting that there may be other molecular binding targets for OSW-1. 
Yamada et al. (2014), using fluorescent OSW-1 demonstrated that the putative binding 
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targets of OSW-1 could be located in the ER and golgi apparatus since the fluorescent OSW-
1 molecule localized with high affinity to these organelles in the cell (82). Based on these 
studies and my own research results I postulate that OSW-1 potentially interacts with a 
ganglioside or lipid signaling protein which is primarily located in the ER/golgi apparatus of 
the cell.        
 SREBP is a master transcription factor regulating cholesterol and fatty acid 
biosynthesis (167). The premature and mature forms of SREBP reside in the ER and golgi 
apparatus, before being cleaved by serine proteases and transported to the nucleus (214).  
Further, SREBP expression correlates with GD3 expression status of the cell (10). Hence, I 
plan to investigate if OSW-1 directly interacts with SREBP in melanoma cells. Below I 
outline the experimental approaches I would employ to test this hypothesis.  
(a) I would perform Chromatin Immunoprecipation (ChIP) for SREBP binding DNA 
elements in the control and OSW-1 treated cells. I would then perform real time-PCR 
experiment with the ChIP output DNA product to detect the expression of SREBP target 
genes including FASN and HMGCR. If OSW-1 directly interacted with SREBP, then the 
expression of FASN and HMGCR genes would be suppressed in the OSW-1 treated samples. 
(b) Biotinylated OSW-1 (75) will be used for this experimental design. Streptavidin magnetic 
beads (Solulink, San Diego, CA) may be used to isolate proteins that bind to biotinylated 
OSW-1 in an experimental design similar to affinity chromatography. Gel electrophoresis 
and quantitative mass spectrometry will then be performed with the product protein sample 
from the streptavidin beads-biotinylated OSW-1 pull down assay to identify the interaction 
partners of OSW-1, including SREBP-1. 
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 The second approach of using the streptavidin beads-biotinylated OSW-1 pull down 
assay (similar design as affinity chromatography) will be extremely useful in identifying the 
interaction protein partners of OSW-1. It would also be important to determine the effect of 
OSW-1 on the expression of GD3 synthase expression regulatory proteins such as TWIST, 
UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE), and amyloid precursor protein (APP) 
by immunoprecipitation, streptavidin beads-biotinylated OSW-1 pull down assay and 
western blotting (165, 166, 215). 
 
5.2.3 Oxidative stress based strategies to combat drug resistance in melanoma using 
PEITC 
 My results demonstrate that combination of PEITC with either TMZ or BCNU 
induces a synergistic drug cytotoxic effect. This increased cell death due to 
PEITC+TMZ/BCNU co-treatment in melanoma cells was characterized by enhanced 
depletion of glutathione and consequent ROS accumulation in cells. Prior studies have shown 
BCNU inhibits glutathione reductase in blood cells (194). My results indicate that treatment 
of melanoma cells with 100 µM BCNU or 0.5 mM TMZ for 24 h causes modest glutathione 
inhibition. However, supplementation of PEITC (5 µM) during the last 3 h triggered 
significant glutathione depletion. Glutathione impairment occurred much earlier than cell 
death implying that it is an important mechanism regulating the anticancer effect of PEITC ± 
BCNU/TMZ drug combination in melanoma cells. I postulate that PEITC would promote 
increased cytotoxicity in TMZ/BCNU treated cells due to its ability to conjugate with and 
export GSH out of the cell thus limiting drug resistance to TMZ/BCNU by Glutathione efflux 
pumps. This in combination with inhibition of GR by BCNU may lead to a higher cell death.          
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To test this possibility, I would examine intracellular as well as culture media concentrations 
of glutathione and PEITC after PEITC ± TMZ/BCNU treatments in melanoma cells. 
Furthermore, I would also investigate the effect of TMZ/BCNU/PEITC treatment on 
GPX/GR enzyme activity in melanoma cells.  
ROS generation and ERK1/2-mediated protective autophagy has been reported to 
cause resistance to Temozolomide in glioblastoma cells (216, 217). I propose that 
combination of PEITC with TMZ/BCNU would push the ROS generation triggered by these 
alkylating agents beyond the cell’s tolerance levels leading to massive toxicity. Figure 4.17 
A, B and C describes that PEITC + BCNU/TMZ treatment causes elevated ROS, nitric oxide 
and mitochondrial superoxide generation. Of specific interest is the induction mitochondrial 
superoxide by this drug combination. Inhibition of oxidative phosphorylation may cause 
superoxide accumulation in the mitochondria. Hence I would perform western blot as well as 
use Seahorse Bioscience XF24 extracellular flux analyzer to investigate the effect of PEITC 
+ TMZ/BCNU drug combination on mitochondrial respiration and oxygen consumption. 
Finally, I would test the efficacy of this PEITC + TMZ/BCNU drug combination in vivo 
using athymic nude mice. Khor et al., demonstrated that i.p. injections of PEITC (2.5 µmol, 
3X per week) and curcumin (3 µmol, 3X per week) in human PC-3 prostate xenografts in 
immunodeficient mice significantly reduced tumor growth (218). I propose to test the effect 
of PEITC ± TMZ/BCNU in immunodeficient mice inoculated with A375SM cells with 
optimized drug dosage and treatment times. 
          Recent studies have indicated that the clinical mutant BRAF inhibitor, vemurafenib, 
causes ROS stress in melanoma cells (204). Combination of vemurafenib with ROS inducing 
agents might be a worthwhile strategy to eliminate these tumors. Important PEITC may be 
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effective in killing vemurafenib resistant tumors since these are characterized by elevated 
intrinsic oxidative stress compared to the vemurafenib sensitive melanomas.   
 Both OSW-1 and PEITC induced cell death is characterized by elevations in ROS 
levels and mitochondria dependent mechanisms of action. Hence it will be worthwhile to 
characterize the combinatorial drug effect of OSW-1 and PEITC in melanoma cells. In this 
study, the effect of OSW-1 + PEITC combination on various molecular markers such as 
glutathione, mitochondrial VDAC1, gangliosides GD3 and GD2, nitric oxide and 
superoxides will be examined. It may be crucial to be compare and correlate the basal 
expression and drug induced changes of these markers in a particular cell line to its 
sensitivity to OSW-1+PEITC treatment. This type of analysis will be of clinical significance 
as it may lead to the identification of biomarkers that would predict patient response to this 
combinatorial OSW-1+PEITC drug treatment strategy.      
 Therapeutic selectivity is an important characteristic of any successful 
pharmacological agent. In this dissertation, I elucidate the mechanisms of anticancer activity 
and therapeutic selectivity of two novel inhibitors, OSW-1 and PEITC. OSW-1 exerts its 
antiproliferative effect by inhibiting ganglioside GD3 expression and causing VDAC1 
activation, subsequently leading to acute autophagy. PEITC relies on the differential redox 
biology between the cancer cells and normal melanocytes to preferentially eliminate 
melanoma cells. Both OSW-1 and PEITC employ relatively novel therapeutic strategies to 
effectively eliminate malignant melanomas and warrant further testing in pre-clinical and 
clinical settings. 
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